Pyridine derivatives having N-linked cyclic substituents as cGAS inhibitors

Abstract

To provide compounds as new proline derivatives, and to provide a pharmaceutical composition comprising the compounds for the treatment of diseases such as systemic lupus erythematosus, systemic sclerosis, non-alcoholic steatohepatitis, interstitial lung disease and idiopathic pulmonary fibrosis.SOLUTION: There are provided new proline derivatives of formula (I) as cGAS inhibitors, or pharmaceutical compositions comprising a prodrug, a pharmaceutically acceptable salt, or a stereoisomer of the compound.SELECTED DRAWING: None

Description

[Technical Field]

[0001] 1. Background of the Invention 1.1 cGAS inhibitors Innate immunity is considered the most important stress response that protects host cells from invading pathogens and the initiation of signaling to the adaptive immune system. These processes are triggered by conserved pathogen-associated molecular patterns (PAMPs) through sensing by diverse pattern recognition receptors (PRRs) and subsequent activation of cytokine and type I interferon gene expression. Major antigen-presenting cells, such as monocytes, macrophages, and dendritic cells, produce type I interferons, which are crucial for inducing adaptive T cell and B cell immune system responses. Major PRRs detect immature or unmodified nucleic acids that are abnormally localized, i.e., mislocated, on the cell surface, inside the lysosomal membrane, or within other cellular compartments (Barbalat et al., Annu. Rev. Immunol. 29, 185-214 (2011)). The cyclic GMP-AMP synthase (cGAS, UniProtKB - Q8N884) is the primary sensor for abnormal double-stranded DNA (dsDNA) originating from pathogens or resulting from mislocalization or misprocessing of nuclear or mitochondrial cellular dsDNA (Sun et al., Science 339, 786-791 (2013); Wu et al., Science 339, 826-830 (2013); Ablasser et al., Nature 498, 380-384 (2013)). Binding of dsDNA to cGAS activates the reaction between GTP and ATP to form the cyclic dinucleotide GMP-AMP (called cGAMP). cGAMP then moves to the endoplasmic reticulum membrane anchored adapter protein, i.e., the interferon gene stimulator (STING), and activates it. Activated STING recruits and activates tank-binding kinase 1 (TBK1), and then phosphorylates the interferon regulatory factor (IRF) transcription factor family, inducing cytokine and type I interferon mRNA expression.

[0002] The important role of cGAS in dsDNA sensing has been confirmed in various pathogens (Hansen et al., EMBOJ. 33, 1654 (2014)), viruses (Ma et al., PNAS 112, E4306 (2015)), and retroviruses (Gao et al., Science 341, 903-906 (2013)). Furthermore, cGAS is essential for various other biological processes, such as cellular senescence (Yang et al., PNAS 114, E4612 (2017), Gluck et al., Nat. Cell Biol. 19, 1061-1070 (2017)) and for the recognition of ruptured micronuclei in the surveillance of potential cancer cells (Mackenzie et al., Nature 548, 461-465 (2017); Harding et al., Nature 548, 466-470 (2017)). The cGAS pathway is crucial for host defense against invading pathogens, but cellular stress and genetic factors can also trigger the production of abnormal cellular dsDNA, for example, through nuclear or mitochondrial leakage, thereby inducing an autoinflammatory response. Eicardi-Goutierre syndrome (AGS; Crow et al., Nat. Genet. 38, 917-920 (2006)), a severe autoimmune disorder similar to lupus, is caused by loss-of-function mutations in TREX1, a major DNA exonuclease that degrades abnormal DNA in the cytosol. Knockout of cGAS in TREX1-deficient mice otherwise blocked the lethal autoimmune response that supports cGAS as a driver of interferonopathy (Gray et al., J. Immunol. 195, 1939-1943 (2015); Gao et al., PNAS 112, E5699-E5705 (2015)). Similarly, embryonic lethality caused by deletion of DNAse2, an endonuclease that leads to excessive DNA degradation within lysosomes during endocytosis, was completely rescued by further knockout of cGAS (Gao et. al, PNAS 112, E5699-E5705 (2015)) or STING (Ahn et al., PNAS 109, 19386-19391 (2012)). These findings support cGAS as a drug target, suggesting that inhibition of cGAS, with the involvement of anti-dsDNA antibodies, could prevent autoinflammation and provide a therapeutic strategy for treating diseases such as systemic lupus erythematosus (SLE) (Pisetsky et al., Nat. Rev. Rheumatol. 12, 102-110 (2016)). [Background technology]

[0003] 1.2 Prior art Due to the understanding that inhibiting the cGAS pathway can prevent autoinflammation and provide therapeutic strategies for treating, for example, autoimmune diseases, many efforts have been made to develop cGAS inhibitors. For example, WO 2019 / 241787 disclosed methyl 4-amino-6-(phenylamino)-1,3,5-triazine-2-carboxylate, such as CU-32 and CU-76, as cGAS inhibitors having "in vitro hcGAS IC50 values" slightly smaller than 1 μM (IC50(CU-32) = 0.66 μM and IC50(CU-76 = 0.27 μM). In Hall et al., PLoS ONE 12(9); e0184843 (2017), compound PF-06928215 was published as a cGAS inhibitor with an "in vitro hcGAS IC50 value" of 0.049 μM, as measured by fluorescence polarization assay. However, compound PF-06928215 did not exhibit acceptable cellular activity as a cGAS inhibitor. WO 2020 / 142729 disclosed (benzoflo[3,2-d]pyrimidine-4-yl)pyrrolidine-2-carboxylic acid derivatives as cGAS inhibitors for the treatment of autoimmune disorders such as Eicardi-Gutierre syndrome (AGS), lupus erythematosus, scleroderma, inflammatory bowel disease, and non-alcoholic steatohepatitis (NASH). However, the compounds of the present invention differ from the (benzoflo[3,2-d]pyrimidine-4-yl)pyrrolidine-2-carboxylic acid derivatives of WO 2020 / 142729 in that they have a completely different substitution pattern at the 4-position of the pyrrolidine ring.

[0004] Recently introduced cGAS inhibitors, such as those described in WO 2020 / 142729, typically exhibit insufficient cellular cGAS inhibitory efficacy (IC50 values ​​for inhibition of the cGAS / STING pathway, measured by cell assays, are generally greater than 1 μM, often greater than 5 μM). However, for a compound to reliably demonstrate therapeutic effects in patients, it must exhibit not only satisfactory biochemical (in vitro) inhibitory efficacy ("hcGAS IC50") but also satisfactory cellular inhibitory efficacy (e.g., inhibition of IFN induction in virus-stimulated THP-1 cells (THP1)). (vir)It is important to provide therapeutic cGAS inhibitors by demonstrating an IC50. Other important characteristics that can predict the success of cGAS inhibitor development as a therapeutic agent are satisfactory cGAS selectivity (against off-target activity) and acceptable inhibitory efficacy in human whole blood.

[0005] Surprisingly, it has now been found that compounds of formula (I) and formula (I') simultaneously exhibit the following three properties: • A satisfactory "biochemical (in vitro) IC50 value for cGAS inhibition" (≤100 nM, preferably ≤50 nM, especially ≤10 nM hcGAS IC50), • Satisfactory inhibition of IFN induction in virus-stimulated THP-1 cells (≤1 μM, preferably ≤500 nM, more preferably ≤100 nM, especially ≤50 nM of THP1 IC50) (vir) ) and • Satisfactory selectivity for cGAS inhibition (Ratio THP1 IC50 ≥ 10, more preferably ≥ 50, even more preferably ≥ 500, especially ≥ 1000) (cGAMP) / THP1 IC50 (vir) ). Furthermore, the compounds of formula (I) and formula (I') also exhibit acceptable IC50 values ​​for IFN-induced inhibition, preferably ≤5000 nM, more preferably ≤1000 nM, and especially ≤100 nM, for cGAS inhibition in a dsDNA-stimulated human whole blood assay (hWB IC50).

[0006] The cGAS of the present invention, possessing a specific pharmacological profile that combines high selectivity for cGAS inhibition with excellent in vitro inhibitory efficacy and superior cytotoxicity, is highly likely to exhibit favorable therapeutic effects in patients. Due to their high cytotoxicity, compounds with this specific pharmacological profile can cross the cell membrane barrier and reach their intracellular target sites, and due to their selectivity to exclusively inhibit cGAS activity, these compounds should not exhibit undesirable off-target effects, such as adverse effects or cytotoxic effects anywhere in the downstream signaling pathway of cGAS.

Summary of the Invention

[0007] 2 Description of the Invention The present invention relates to the following formula (I)

Chemical

[0008] (wherein R 1 is selected from methyl, ethyl, halomethyl, haloethyl and halogen, G is selected from O, NR 8 , CH2, C and CR 8 R 9 is selected from, R 2 is selected from H, halogen, cyclopropyl, C 1-3 -alkyl, -C 2-5 -alkynyl, -S-methyl and CN, or R 2 is a cyclic group, and this cyclic group is selected from the group consisting of phenyl or 5- to 6-membered heteroaryl containing from 1, 2, 3 or 4 heteroatoms independently selected from N, S and O, and this cyclic group is substituted with one or two identical or different substituents R 10 , R 3 is H or methyl, R 4 is H or methyl, R 5 [[ID=​​​​​​​​​​​​​​​​​​​)-alkyl and halo-(C 1-3 )-Selected from alkyl groups, R 8 It is selected from CN, H and methyl, R 9 It is selected from H, methyl and halogen, or R 9 It does not need to exist, Here, each R 10 These are hydrogen, halogen, haloalkyl, -methyl, -ethyl, -NH-CO-methyl, -N(CH3)2, -CH2-OH, -NH(CH3), -O-(C 1-3 -alkyl), -CN, -S-CH3, -CO-NH2, -CH2-NH(CH3), -CH2-NH2, -SO-(CH3), cyclopropyl and -OR 11 Independently selected from the group consisting of, Each R 11 It is independently selected from a 5-membered or 6-membered heteroring having one or two heteroatoms independently selected from N, O, and S, Or G is CR 8 R 9 And R 5 and R 9 It does not exist, and R 8 and R 6 and R 8 and R 6 The two intermediate carbon atoms form a condensed five-membered aromatic or non-aromatic heteroring containing one, two, or three heteroatoms independently selected from N, S, and O, respectively. Or G is CR 8 R 9 And R 8 and R 9 However, R 8 and R 9 (It forms a diazirine ring together with the intermediate C atom.) compounds and relating to prodrugs or pharmaceutically acceptable salts of these compounds.

[0009] A preferred embodiment of the present invention is given by the following formula (I') [ka] (In the formula, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 (and G is as defined above) The above compounds that fall within the range and relating to prodrugs or pharmaceutically acceptable salts of these compounds.

[0010] Another preferred embodiment of the present invention is, R 7 is H, F, Cl, methyl, ethyl, halomethyl, or haloethyl. The above compound of formula (I) or formula (I') and relating to prodrugs or pharmaceutically acceptable salts of these compounds. In another preferred embodiment, the present invention is R 1 is halomethyl, haloethyl, or methyl. The above compound of formula (I) or formula (I') and relating to prodrugs or pharmaceutically acceptable salts of these compounds. Further preferred embodiments of the present invention are: R 1 However, it is a fluoromethyl selected from the group consisting of -CF3, -CHF2, and -CH2F. The above compound of formula (I) or formula (I') This refers to prodrugs or pharmaceutically acceptable salts of these compounds. In another preferred embodiment, the present invention is R 3 and R 4 At least one of them is methyl, The above compound of formula (I) or formula (I') and relating to prodrugs or pharmaceutically acceptable salts of these compounds.

[0011] Another preferred embodiment of the present invention is, R 3 and R 4 One of them is methyl, and the other is H. The above compound of formula (I) or formula (I') and relating to prodrugs or pharmaceutically acceptable salts of these compounds. In another preferred embodiment, the present invention is G is O, The above compound of formula (I) or formula (I') and relating to prodrugs or pharmaceutically acceptable salts of these compounds. Another preferred embodiment of the present invention is, G is O, and R 3 and R 4 One of them is methyl, and the other is H. The above compound of formula (I) or formula (I') and relating to prodrugs or pharmaceutically acceptable salts of these compounds. In another preferred embodiment, the present invention is G is O, R 4 is methyl, R 3 H is, and R 5 and R 6 They together form an oxetane ring. The above compound of formula (I) or formula (I') and relating to prodrugs or pharmaceutically acceptable salts of these compounds.

[0012] Another preferred embodiment of the present invention is, R 2 However, selected from the group consisting of H, ethynyl, 1-propynyl, -S-methyl and halogen, The above compound of formula (I) or formula (I') and relating to prodrugs or pharmaceutically acceptable salts of these compounds. In another preferred embodiment, the present invention is R 2 is ethinyl, The above compound of formula (I) or formula (I') This refers to prodrugs or pharmaceutically acceptable salts of these compounds. Another preferred embodiment of the present invention is, R 4 is methyl, R 3 H is, G is O, R 5 and R 6 Together they form an oxetane ring, R 2 However, selected from the group consisting of H, ethynyl, 1-propynyl, -S-methyl and halogen, The above compound of formula (I) or formula (I') and relating to prodrugs or pharmaceutically acceptable salts of these compounds.

[0013] In another preferred embodiment, the present invention is R 2 This is a cyclic group, and this cyclic group is selected from the group consisting of 5-membered to 6-membered heteroaryl compounds containing 1, 2, or 3 heteroatoms selected from phenyl or N, S, and O. This cyclic group has one or two identical or different substituents R 10 Replaced by, Each R 10 These include hydrogen, halogens, haloalkyls, -methyl, -ethyl, -NH-CO-methyl, -N(CH3)2, -CH2-OH, -NH(CH3), -O-CH3, -CN, -S-CH3, -CO-NH2, -CH2-NH(CH3), -CH2-NH2, -SO-(CH3), cyclopropyl and -OR 11 Independently selected from the group consisting of, Each R 11 This is independently selected from a 5-membered or 6-membered aromatic or non-aromatic heteroring having one or two heteroatoms independently selected from N and O, respectively. The above compound of formula (I) or formula (I') This refers to prodrugs or pharmaceutically acceptable salts of these compounds. Further preferred embodiments of the present invention are: R2 is a cyclic group selected from the group consisting of pyrazolyl, pyridinyl, imidazolyl, phenyl and isoxazolyl, this cyclic group is substituted with one or two identical or different substituents R 10 and, each R 10 is independently selected from the group consisting of hydrogen, halogen, haloalkyl, -methyl, -ethyl, -NH-CO-methyl, -N(CH3)2, -CH2-OH, -NH(CH3), -O-CH3, -CN, -S-CH3, -CO-NH2, -CH2-NH(CH3), -CH2-NH2, -SO-(CH3), cyclopropyl and -O-R 11 and, each R 11 is tetrahydropyran, the above compounds of formula (I) or formula (I') and prodrugs or pharmaceutically acceptable salts of these compounds are referred to.

[0014] In another preferred embodiment, the present invention where G is O, R 3 and R 4 one of them is methyl and the other is H, R 2 is a cyclic group selected from the group consisting of pyrazolyl, pyridinyl, imidazolyl, phenyl and isoxazolyl, this cyclic group is substituted with one or two identical or different substituents R 10 and, each R 10 is independently selected from the group consisting of hydrogen, halogen, haloalkyl, -methyl, -ethyl, -NH-CO-methyl, -N(CH3)2, -CH2-OH, -NH(CH3), -O-CH3, -CN, -S-CH3, -CO-NH2, -CH2-NH(CH3), -CH2-NH2, -SO-(CH3), cyclopropyl and -O-R<​​​​​​​​and prodrugs or pharmaceutically acceptable salts of these compounds. In another preferred embodiment, the present invention R 2 is a cyclic group selected from the group consisting of pyrazolyl, pyridinyl, imidazolyl, phenyl and isoxazolyl,[[]] wherein this cyclic group is substituted with one or two identical or different substituents R 10 and each R 10 is independently selected from the group consisting of hydrogen, halogen, haloalkyl, -methyl, -ethyl, -NH-CO-methyl, -N(CH3)2, -CH2-OH, -NH(CH3), -O-CH3, -CN, -S-CH3, -CO-NH2, -CH2-NH(CH3), -CH2-NH2, -SO-(CH3), cyclopropyl and -O-R 11 and each R 11 is tetrahydropyran,[[]] G is O,[[]] R 3 and R 4 one of which is methyl and the other is H,[[]] and R 5 and R 6 together form an oxetane ring,[[]] the above compounds of formula (I) or formula (I’)[[]] and prodrugs or pharmaceutically acceptable salts of these compounds.

[0015] In another preferred embodiment, the present invention G is CR 8 R 9 and R 8 and R 6 with the two middle C atoms of R 8 and R 6 form a fused 5-membered aromatic heterocycle containing 1 or 2 heteroatoms independently selected from N and O, which is selected from a fused isoxazolyl ring, a fused pyrazolyl ring, a fused pyrrolyl ring and a fused furanyl ring,[[]][[ID=!59]] and R 9 and R 5 are absent,[[]] The above compound of formula (I) or formula (I') This refers to prodrugs or pharmaceutically acceptable salts of these compounds.

[0016] Another particularly preferred embodiment of the present invention is the following compound [ka]

[0017] [ka]

[0018] [ka]

[0019] [ka]

[0020] [ka]

[0021] [ka]

[0022] [ka]

[0023] [ka] Selected from the group consisting of, The above compound of formula (I) or formula (I') This refers to prodrugs or pharmaceutically acceptable salts of these compounds.

[0024] In another embodiment, the present invention is For use in treating diseases that can be treated with cGAS inhibitors, This relates to the above-mentioned compound of formula (I) or formula (I'). In preferred embodiments, the present invention refers to the compound of formula (I) or formula (I') for use in the treatment of diseases selected from the group consisting of systemic lupus erythematosus (SLE), interferonopathy, Eicardi-Gutierre syndrome, age-related macular degeneration (AMD), amyotrophic lateral sclerosis (ALS), inflammatory bowel disease (IBD), chronic obstructive pulmonary disease (COPD), Bloom syndrome, Sjögren's syndrome, Parkinson's disease, heart failure and cancer, systemic sclerosis (SSc), non-alcoholic steatohepatitis (NASH), interstitial lung disease (ILD), preferably progressive fibrous interstitial lung disease (PF-ILD), and particularly idiopathic pulmonary fibrosis (IPF).

[0025] In a more preferred embodiment, the present invention relates to the compound of formula (I) or formula (I') for use in the treatment of a disease selected from the group consisting of systemic lupus erythematosus (SLE), interferonopathy, Eicardi-Gutierre syndrome, age-related macular degeneration (AMD), amyotrophic lateral sclerosis (ALS), inflammatory bowel disease (IBD), chronic obstructive pulmonary disease (COPD), Bloom syndrome, Sjögren's syndrome, and Parkinson's disease. In another, more preferred embodiment, the present invention relates to the compounds of formula (I) or formula (I') for use in the treatment of fibrous diseases selected from the group consisting of systemic sclerosis (SSc), interferonopathy, non-alcoholic steatohepatitis (NASH), interstitial lung disease (ILD), preferably progressive fibrous interstitial lung disease (PF-ILD), and particularly idiopathic pulmonary fibrosis (IPF). In another, more preferred embodiment, the present invention relates to the compounds of formula (I) or formula (I') for use in the treatment of diseases selected from the group consisting of age-related macular degeneration (AMD), heart failure, COVID-19 / SARS-CoV-2 infection, nephritis, renal fibrosis, dysmetabolism, vascular disease, cardiovascular disease, and cancer.

[0026] In another embodiment, the present invention relates to a pharmaceutical composition comprising at least one of the compounds of formula (I) or formula (I') and one or more pharmaceutically acceptable carriers and / or excipients, which may be optionally included.

[0027] In another preferred embodiment, the present invention relates to the following formula (IV) according to synthesis scheme 1. [ka] Alternatively, the following formula (V) according to synthesis scheme 1

[0028] [ka] Alternatively, the following formula (X) according to synthesis scheme 2

[0029] [ka] Alternatively, the following formula (XI) according to synthesis scheme 2

[0030] [ka] It refers to an intermediate, Here, G, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 This is as defined above, X is either F or NO2. PG is a protecting group selected from the group consisting of tert-butoxycarbonyl (BOC), benzyloxycarbonyl (Cbz), fluorenylmethylenoxycarbonyl (Fmoc), allyloxycarbonyl (Alloc), benzyl (Bn), p-methoxybenzyl (PMB), 3,4-methoxybenzyl (DMPM), p-methoxyphenyl (PMP), tosyl (Ts), trichloroethyl chloroformate (Troc), acetyl (Ac), or benzoyl (Bn).

[0031] In a further preferred embodiment, the present invention relates to a prodrug of either the compound of formula (I) or formula (I'), Here, this prodrug is within the range of formula (A) below.

[0032] [ka] Or within the range of the following formula (A')

[0033] [ka] (In the formula, G, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 This is as defined above, R 12 C 1-4- Alkyl, aryl, -CH2-aryl, NH-SO2-C 1-3 -It is alkyl.) Enter. In particular, the present invention is R 12 The present invention relates to the above-mentioned prodrug of formula (A) or formula (A'), wherein is methyl.

[0034] In another preferred embodiment, the present invention relates to a combination of a compound of formula (I) or formula (I') with one or more active agents selected from the group consisting of anti-inflammatory agents, anti-fibrotic agents, anti-allergic / antihistamines, bronchodilators, β2 agonists / beta-mimetics, adrenergic agonists, anticholinergics, methotrexate, mycophenolate mofetil, leukotriene modifiers, JAK inhibitors, anti-interleukin antibodies, nonspecific immunotherapeutic agents such as interferon or other cytokines / chemokines, cytokine / chemokine receptor modifiers, Toll-like receptor agonists, immune checkpoint modulators, anti-TNF antibodies such as Humira (trademark), anti-BAFF antibodies such as belimumab and etanercept. In further, particularly preferred embodiments, the present invention relates to a combination of a compound of formula (I) or formula (I') with one or more antifibrotic agents selected from the group consisting of pirfenidone and nintedanib. In further particularly preferred embodiments, the present invention relates to a combination of a compound of formula (I) or formula (I') with one or more anti-inflammatory agents selected from the group consisting of NSAIDs and corticosteroids. In further particularly preferred embodiments, the present invention relates to a combination of a compound of formula (I) or formula (I') with one or more active agents selected from the group consisting of bronchodilators, β2 agonists / beta-mimetics, adrenergic agonists and anticholinergics. In further particularly preferred embodiments, the present invention relates to a combination of a compound of formula (I) or formula (I') with one or more anti-interleukin antibodies selected from the group consisting of anti-IL23 antibodies, such as risankizumab, anti-IL17 antibodies, anti-IL1 antibodies, anti-IL4 antibodies, anti-IL13 antibodies, anti-IL-5 antibodies, anti-IL-6 antibodies, such as Actemra (trademark), anti-IL-12 antibodies, and anti-IL-15 antibodies. In another preferred embodiment, the present invention relates to a pharmaceutical composition comprising a compound of formula (I) or formula (I') in combination with any of the above-mentioned active agents. [Modes for carrying out the invention]

[0035] 3. Terms and Definitions Used Unless otherwise specified, all substituents are independent of each other. For example, several carbon atoms on a given group. 1-6 -If alkyl is a possible substituent, for example, in the case of three substituents, C 1-6 -Alkyl can independently represent methyl, n-propyl, and tert-butyl. The term “C 1-6 -alkyl (including those that are part of other groups) refers to branched and unbranched alkyl groups having 1 to 6 carbon atoms, and the term "C 1-3 "-alkyl" refers to branched and unbranched alkyl groups having 1 to 3 carbon atoms. Therefore, "C 1-4 "-alkyl" refers to branched and unbranched alkyl groups having 1 to 4 carbon atoms. Alkyl groups having 1 to 4 carbon atoms are preferred. Examples of these include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, and hexyl. Abbreviations such as Me, Et, n-Pr, i-Pr, n-Bu, i-Bu, t-Bu, etc. may be optionally used for the above groups. Unless otherwise specified, the definitions of propyl, butyl, pentyl, and hexyl include all possible isomers of the group in question. Therefore, for example, propyl includes n-propyl and isopropyl, and butyl includes isobutyl, sec-butyl, and tert-butyl, etc.

[0036] The term “C 1-6 -Alkylene (including those that are part of other groups) refers to branched and unbranched alkylene groups having 1 to 6 carbon atoms, and the term "C 1-4"-Alkylene" refers to branched and unbranched alkylene groups having 1 to 4 carbon atoms. Alkylene groups having 1 to 4 carbon atoms are preferred. Examples of these include methylene, ethylene, propylene, 1-methylethylene, butylene, 1-methylpropylene, 1,1-dimethylethylene, 1,2-dimethylethylene, pentylene, 1,1-dimethylpropylene, 2,2-dimethylpropylene, 1,2-dimethylpropylene, 1,3-dimethylpropylene, and hexylene. Unless otherwise specified, defined propylene, butylene, pentylene, and hexylene include all possible isomers of the group in question having the same number of carbon atoms. Therefore, for example, propyl also includes 1-methylethylene, and butylene includes 1-methylpropylene, 1,1-dimethylethylene, 1,2-dimethylethylene, etc.

[0037] When a carbon chain is substituted with a group that forms a carbocyclic ring having 3, 5, or 6 carbon atoms together with one or two carbon atoms of the alkylene chain, this includes, among other things, the rings in the examples below. [ka]

[0038] The term “C 2-6 -Alkenyl (including those that are part of other groups) refers to branched and unbranched alkenyl groups having 2 to 6 carbon atoms, provided that they have at least one double bond. 2-4"-Alkenyl" refers to branched and unbranched alkenyl groups having 2 to 4 carbon atoms, provided that they have at least one double bond. Alkenyl groups having 2 to 4 carbon atoms are preferred. Examples include ethenyl or vinyl, propenyl, butenyl, pentenyl, or hexenyl. Unless otherwise specified, the definitions of propenyl, butenyl, pentenyl, and hexenyl include all possible isomers of the group in question. For example, propenyl includes 1-propenyl and 2-propenyl, and butenyl includes 1-butenyl, 2-butenyl, and 3-butenyl, 1-methyl-1-propenyl, 1-methyl-2-propenyl, etc. The term “C 2-5 -Alkynyl (including those that are part of other groups) refers to branched and unbranched alkynyl groups having 2 to 5 carbon atoms, provided that they have at least one triple bond. 2-4 The term "-alkynyl" refers to branched and unbranched alkynyl groups having 2 to 4 carbon atoms, provided that they have at least one triple bond. Alkynyl groups having 2 to 4 carbon atoms are preferred. The term “C 2-6 -Alkenylene (including those that are part of other groups) refers to branched and unbranched alkenylene groups having 2 to 6 carbon atoms, and the term "C 2-4"-Alkenylene" refers to branched and unbranched alkylene groups having 2 to 4 carbon atoms. Alkenylene groups having 2 to 4 carbon atoms are preferred. Examples of these include ethenylene, propenylene, 1-methylethenylene, butenylene, 1-methylpropenylene, 1,1-dimethylethenylene, 1,2-dimethylethenylene, pentenylene, 1,1-dimethylpropenylene, 2,2-dimethylpropenylene, 1,2-dimethylpropenylene, 1,3-dimethylpropenylene, and hexenylene. Unless otherwise specified, the defined propenylene, butenylene, pentenylene, and hexenylene include all possible isomers of the group in question having the same number of carbon atoms. Therefore, for example, propenyl also includes 1-methylethenylene, and butenylene also includes 1-methylpropenylene, 1,1-dimethylethenylene, and 1,2-dimethylethenylene.

[0039] The term "aryl" (including when it is part of another group) refers to an aromatic ring system having 6 or 10 carbon atoms. Examples include phenyl or naphthyl, with phenyl being the preferred aryl group. Unless otherwise specified, aromatic groups may be substituted with one or more groups selected from methyl, ethyl, isopropyl, tert-butyl, hydroxy, fluorine, chlorine, bromine, and iodine. The term "aryl-C" 1-6 -Alkylene (including those that are part of other groups) means branched and unbranched alkylene groups having 1 to 6 carbon atoms, which are substituted with aromatic ring systems having 6 or 10 carbon atoms. Examples include benzyl, 1-phenylethyl or 2-phenylethyl and 1-naphthylethyl or 2-naphthylethyl. Unless otherwise specified, aromatic groups may be substituted with one or more groups selected from methyl, ethyl, isopropyl, tert-butyl, hydroxy, fluorine, chlorine, bromine, and iodine. The term "heteroaryl-C" 1-6 -alkylene (including those that are part of other groups) is "aryl-C 1-6- This refers to branched and unbranched alkylene groups that are already present in "alkylene" but are substituted with heteroaryl groups and have 1 to 6 carbon atoms. Unless otherwise specified, this type of heteroaryl may contain one, two, three, or four heteroatoms selected from oxygen, sulfur, and nitrogen, and may contain enough conjugated double bonds to form an aromatic system, including a five- or six-membered heterocyclic aromatic group or a five- to ten-membered bicyclic heteroaryl ring. The following are examples of five- or six-membered heterocyclic aromatic groups and bicyclic heteroaryl rings.

[0040] [ka]

[0041] Unless otherwise specified, these heteroaryl groups may be substituted with one or more groups selected from methyl, ethyl, isopropyl, tert-butyl, hydroxy, amino, nitro, alkoxy, fluorine, chlorine, bromine, and iodine. The following is heteroaryl-C 1-6 - An example of alkylene.

[0042] [ka]

[0043] The term “C 1-6 -Haloalkyl (including those that are part of another group) refers to branched and unbranched alkyl groups having 1 to 6 carbon atoms that are substituted with one or more halogen atoms. 1-4 "-Haloalkyl" refers to branched and unbranched alkyl groups having 1 to 4 carbon atoms and substituted with one or more halogen atoms. Alkyl groups having 1 to 4 carbon atoms are preferred. Examples include CF3, CHF2, CH2F, and CH2CF3. The term “C 3-7"-cycloalkyl" (including those that are part of other groups) means a cyclic alkyl group having 3 to 7 carbon atoms unless otherwise specified. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl. Unless otherwise specified, cyclic alkyl groups may be substituted with one or more groups selected from methyl, ethyl, isopropyl, tert-butyl, hydroxy, fluorine, chlorine, bromine, and iodine. Unless otherwise specified, the term "C" 3-10 "-Cycloalkyl" refers to a monocyclic alkyl group having 3 to 7 carbon atoms, a bicyclic alkyl group having 7 to 10 carbon atoms, or at least one C 1-3 -This also refers to monocyclic alkyl groups bridged by carbon bridges. The term “heterocyclic ring” or “heterocycle” means, unless otherwise specified, a 5-membered, 6-membered, or 7-membered saturated, partially saturated, or unsaturated heterocyclic ring that may contain one, two, or three heteroatoms selected from oxygen, sulfur, and nitrogen, and which may be linked to a molecule via carbon atoms or, if present, nitrogen atoms. The term “saturated heterocyclic ring” is included by the terms “heterocyclic ring” or “heterocycle,” but refers to a 5-membered, 6-membered, or 7-membered saturated ring. Examples are given below.

[0044] [ka]

[0045] The terms "heterocyclic ring" or "heterocyclic group" include the term "partially saturated heterocyclic ring," but unless specifically defined otherwise, the term "partially saturated heterocyclic ring" refers to a 5-membered, 6-membered, or 7-membered partially saturated ring containing one or two double bonds, without forming enough double bonds to create an aromatic system. Examples include the following:

[0046] [ka]

[0047] The terms "heterocyclic ring" or "heterocycle" include, but unless specifically defined otherwise, the terms "heterocyclic aromatic ring," "unsaturated heterocyclic group," or "heteroaryl" refer to a 5- or 6-membered heterocyclic aromatic group or a 5- to 10-membered bicyclic heteroaryl ring that may contain 1, 2, 3, or 4 heteroatoms selected from oxygen, sulfur, and nitrogen, and contain enough conjugated double bonds to form an aromatic system. Examples of 5- or 6-membered heterocyclic aromatic groups are listed below.

[0048] [ka]

[0049] Unless otherwise specified, heterocyclic rings (or heterocycles) may contain keto groups. Examples include the following:

[0050] [ka]

[0051] Although encompassed by the term "cycloalkyl," the term "bicyclic cycloalkyl" generally refers to an 8-membered, 9-membered, or 10-membered bicyclic carbon ring. Examples include the following:

[0052] [ka]

[0053] Although already included by the term "heterocycle," the term "bicyclic heterocycle," unless specifically defined otherwise, generally refers to an 8-membered, 9-membered, or 10-membered bicyclic ring that may contain one or more heteroatoms selected from oxygen, sulfur, and nitrogen, preferably 1 to 4, more preferably 1 to 3, even more preferably 1 to 2, and especially 1 heteroatom. This ring may be linked to a molecule via the carbon atoms of the ring or, if present, via the nitrogen atoms of the ring. Examples include the following:

[0054] [ka]

[0055] Although already included by the term "aryl," the term "bicyclic aryl" refers to a 5- to 10-membered bicyclic aryl ring containing enough conjugated double bonds to form an aromatic system. An example of a bicyclic aryl is naphthyl. Although already included in "heteroaryl," the term "bicyclic heteroaryl" specifically refers to a 5-10 membered bicyclic heteroaryl ring that may contain 1, 2, 3, or 4 heteroatoms selected from oxygen, sulfur, and nitrogen, and contains enough conjugated double bonds to form an aromatic system, unless otherwise defined. The terms "bicyclic cycloalkyl" or "bicyclic aryl" include these, but the terms "condensed cycloalkyl" or "condensed aryl" refer to bicyclic rings where the bridges separating the rings directly represent single bonds. The following are examples of condensed bicyclic cycloalkyls.

[0056] [ka]

[0057] The terms "bicyclic heterocycle" or "bicyclic heteroaryl" include, but the terms "condensed bicyclic heterocycle" or "condensed bicyclic heteroaryl" refer to a bicyclic 5-10 membered heterocycle containing 1, 2, 3, or 4 heteroatoms selected from oxygen, sulfur, and nitrogen, and where the bridges separating the rings directly represent single bonds. "Condensed bicyclic heteroaryl" further contains enough conjugated double bonds to form an aromatic system. Examples include pyrrolidine, indole, indidine, isoindole, indazole, purine, quinoline, isoquinoline, benzimidazole, benzofuran, benzopyran, benzothiazole, benzothiazole, benzoisothiazole, pyridopyrimidine, pteridine, pyridopyrimidine,

[0058] [ka] These are some examples.

[0059] Within the scope of this invention, "halogen" means fluorine, chlorine, bromine, or iodine. Unless otherwise specified, fluorine, chlorine, and bromine are considered preferred halogens. As previously stated, the compounds of formula (I) or (I') may be converted to salts thereof, in particular physiologically and pharmacologically acceptable salts for pharmaceutically acceptable uses. In this specification, the term “pharmaceutically acceptable” refers to compounds, substances, compositions, and / or dosage forms that, within reasonable medical judgment, are suitable for use in contact with human and animal tissues without excessive toxicity, irritation, allergic reactions, or other problems or complications, and which are balanced by a reasonable benefit / risk ratio. These salts may, on the one hand, exist as physiologically and pharmacologically acceptable acid addition salts of the compounds of formula (I) or (I') with inorganic or organic acids. On the other hand, the compounds of formula (I) or (I') may be converted to physiologically and pharmacologically acceptable salts with alkali metal or alkaline earth metal cations as counterions by reaction with inorganic bases. Acid addition salts can be prepared using, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, p-toluenesulfonic acid, acetic acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid, or maleic acid. Mixtures of the above acids can also be used. To prepare alkali metal salts and alkaline earth metal salts of the compound of formula (I) or (I'), hydroxides and hydrides of alkali metals and alkaline earth metals, among which alkali metals, particularly sodium, potassium, magnesium, calcium, zinc, and diethanolamine hydroxides and hydrides, are preferred, with sodium hydroxide and potassium hydroxide being particularly preferred.

[0060] The present invention relates to the compounds in question in the form of optionally individual optical isomers, diastereomers, mixtures of diastereomers, individual enantiomers or mixtures of racemates, in the form of tautomers and in the form of the free base or the corresponding acid addition salts with pharmacologically acceptable acids, such as hydrohalic acids, such as hydrochloric acid or hydrobromic acid, or organic acids, such as oxalic acid, fumaric acid, diglycolic acid or methanesulfonic acid. The compounds of formula (I) or (I') of the present invention may optionally exist as a mixture of diastereomeric isomers, but may also be obtained as pure diastereomers. Compounds with the specific stereochemistry of formula (I') are preferred.

[0061] 4 Synthetic methods The compounds of the present invention and their intermediates can be obtained, for example, by using synthetic methods known to those skilled in the art and described in the literature of organic synthesis. Furthermore, the present invention provides a process for producing the compounds of formula (I) or formula (I'). The optimal reaction conditions and reaction times may vary depending on the individual reactants used. Unless otherwise specified, those skilled in the art can easily select the solvent, temperature, pressure and other reaction conditions. Specific procedures are provided in the synthesis example section. Typically, the progress of the reaction can be monitored by thin layer chromatography (TLC) or liquid chromatography-mass spectrometry (LC-MS), and the intermediates and products can be purified by silica gel chromatography, HPLC and / or recrystallization as required. The following examples are illustrative, and as will be recognized by those skilled in the art, the specific reagents or conditions can be modified for individual compounds as required without undue experimentation. The starting materials and intermediates used in the following methods are commercially available or can be easily prepared from commercially available materials by those skilled in the art. The compounds of formula (I) can be prepared by the methods outlined in Schemes 1 to 4. Here, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7, R 8 , R 9 , R 10 , R 11 For R, R, R, R, and G, they are as defined above. PG is preferably a protecting group selected from the group consisting of tert-butoxycarbonyl (BOC), benzyloxycarbonyl (Cbz), fluorenylmethyleneoxycarbonyl (Fmoc), and allyloxycarbonyl (Alloc).

[0062] Scheme 1:

Chemical Structure

[0063] As shown in Scheme 1, the reaction of (2S,4S)-4-hydroxypyrrolidine-2-carboxylic acid (III) with chloro-pyrimidine (II) in a suitable solvent such as DMSO, in the presence of a suitable base such as diisopropylethylamine, potassium carbonate or sodium hydride, gives the hydroxyproline derivative of formula (IV). The reaction of hydroxyproline (IV) with pyridine of formula (V) (where X is F or NO2) in a suitable solvent such as DMA, DMF or NMP, in the presence of a suitable base such as NaH, gives the compound of formula (I).

[0064] Scheme 2:

Chemical Structure

[0065] As shown in Scheme 2, the reaction of fluoronitropyridine (VI) with a cyclic amine (VII) in a suitable solvent such as acetonitrile and in the presence of a suitable base such as K2CO3 yields the nitropyridine of formula (VIII). This nitropyridine (VIII) can then be reacted with hydroxyproline of formula (IX), whose protecting group PG may be, for example, tert-butoxycarbonyl (BOC), in a suitable solvent such as DMF, NMP, or DMA and in the presence of a suitable base such as NaH, to yield the compound of formula (X). Removal of the protecting group PG from (X) under standard conditions yields the proline derivative of formula (XI). That is, if the PG is BOC, deprotection can be carried out using TFA in a suitable solvent such as acetonitrile. The reaction of compound (XI) with chloropyrimidine of formula (II) in a suitable solvent such as DMSO or DMF and in the presence of a suitable base such as diisopropylethylamine, potassium carbonate, or sodium hydride yields the compound of formula (I). After this general reaction scheme 2, substituent R 2 R is present from the beginning of the reaction sequence of compound (VI) and remains unchanged until compound (I) is obtained (i.e., R 2 (where is H, Br, Cl, aryl or alkynyl), or substituent R 2 R may be introduced at a later stage in synthesis via Suzuki coupling or other arylation reactions known to those skilled in the art. For example, R 2 Compounds of formula (VI), (VIII), (X), or (I), where is Br, I, or OTf, react with a suitable aryl boronate (ester / acid) in a suitable solvent such as dioxane or DMF, in the presence of a suitable base such as Na2CO3, K3PO4, or KOH, and a suitable catalyst such as Pd(dppf)Cl2 or Pd(PPh3)4 (using a suitable ligand such as Xphos), to form R 2 Each compound can be given in which is aryl.

[0066] Separately, R 2Compounds of formula (VI), (VIII), (X), or (I), where R2 is a halogen or OTf, can be reacted with a borating reagent such as bis(pinacolato)diboron in the presence of a suitable catalyst such as Pd(dppf)Cl2 and a suitable base such as potassium acetate to give boronic acid esters. These boronic acid esters can be reacted with a suitable aryl halide by Suzuki coupling in a suitable solvent such as dioxane or DMF, in the presence of a suitable base such as Na2CO3, K3PO4, or KOH and a suitable catalyst such as Pd(dppf)Cl2 or Pd(PPh3)4 (using a suitable ligand such as Xphos) to give the respective compounds where R2 is an aryl. Separately, R 2 Compounds of formula (VI), (VIII), (X), or (I), in which is a halogen, react with a suitable alkyne such as ethynyltris(propane-2-yl)silane in the presence of a suitable catalyst such as PdCl2(PPh3)2 and copper(I) iodide, and a suitable base such as DIPEA in a suitable solvent such as THF, to form R 2 Each of these compounds can be given that is an alkyne. The carboxylic acid functionality of the proline motif (i.e., in the compound of formula (X) or (I)) can be protected with a suitable protecting group such as an alkyl ester during the reaction specific to this sequence, i.e., tert-butyl ester, R 2 It is a suitable protecting group for introducing the aryl portion.

[0067] As shown in Scheme 3, the compound of formula (II) can be prepared. Scheme 3: [ka]

[0068] The reaction of the carbon nitrile of formula (XII) with the anhydride or corresponding acid of formula (XIII) in a suitable solvent such as pyridine yields amide (XIV). When reacted with a suitable chlorinating agent such as phosphorus pentachloride in a suitable solvent such as sulfolane, amide (XIV) undergoes cyclization to form the compound of formula (II). In the alternative synthesis sequence, the compound of formula (XV) reacts with 2-bromoacetamide in a suitable solvent such as ethanol, in the presence of a suitable base such as K2CO3 or KOH, to give the compound of formula (XVII). Compound (XVII) then reacts with dimethylamide of formula (XVIII) in the presence of a suitable chlorinating agent such as phosphorus oxychloride to form the compound of formula (II). In an alternative synthetic sequence, the compound of formula (XV) reacts with bromoacetonitrile in a suitable solvent such as DMF and in the presence of a suitable base such as K2CO3 to give the compound of formula (XIX). This compound is cyclized in a suitable solvent such as THF and in the presence of a suitable base such as tert-butoxide to form carboninitrile (XII), which can be converted to the compound of formula (XIV) as described above, and subsequently to the compound of formula (II). The compound of formula (VII) is commercially available or can be prepared according to the literature, or is described as an example in the experimental section. The compound of formula (VII), as exemplified by the compound of formula (XXIII), can be prepared as shown in Scheme 4.

[0069] Scheme 4: [ka]

[0070] Oxetane-3-one (XXII) reacts with the nitroalkane of formula (XXIII) in a suitable solvent such as methanol to form the compound of formula (XXIV). Hydrogenation of compound (XXIV) in a suitable solvent such as ethanol, in the presence of hydrogen and a suitable catalyst such as Pd(OH)2 / C, yields the compound of formula (XXV). Reaction of compound (XXV) with chloroacetyl chloride in a suitable solvent such as acetonitrile, in the presence of a suitable base such as triethylamine, yields compound (XXVI), which is cyclized in a suitable solvent such as tert-amyl alcohol, under treatment with a suitable base such as tert-butoxide, to form the lactam of formula (XXVII). Reduction of compound (XXVII) in a suitable solvent such as diethyl ether, with a suitable reducing agent such as lithium aluminum hydride, yields the morpholine compound of formula (XXVIII). Additional compounds of the present invention can be prepared by utilizing methods known to those skilled in the art and by further modifications of the compound of formula (I) by the methods shown in the following examples. The presented synthetic route may rely on the use of protecting groups. For example, potentially present reactive groups, such as hydroxyl, carbonyl, carboxyl, amino, alkylamino, or imino, can be protected during the reaction by common protecting groups that are cleaved again after the reaction. Each functionality and the protecting groups suitable for their removal are well known to those skilled in the art, as can be found in the literature of organic synthesis, e.g., “Protecting Groups, 3 rd Edition”, Philip J. Kocienski, Thieme, 2005 or “Protective Groups in Organic Synthesis, 4 th This is described in "Edition," Peter GM Wuts, Theodora W. Greene, John Wiley and Sons, 2007.

[0071] Compounds of general formula (I) can be separated into their diastereomers (ds) as described later. Therefore, for example, a cis / trans mixture can be separated into its cis and trans isomers. A cis / trans mixture can be separated into its cis and trans isomers, for example, by chromatography. A mixture of diastereomers of a compound of general formula (I) can be separated into their diastereomers by methods known to themselves, such as chromatography and / or fractional crystallization, by considering their different physicochemical properties. The racemic intermediate is preferably resolved by chiral phase column chromatography, crystallization from an optically active solvent, or by reacting a derivative such as a salt, ester, or amide with an optically active substance that forms the racemic compound. The salt may form with an enantiomerically pure acid for basic compounds, and with an enantiomerically pure base for acidic compounds. The diastereomer derivative is formed with an enantiomerically pure auxiliary compound, such as an acid, its activated derivative, or an alcohol. Separation of the diastereomer mixture of the salt or derivative thus obtained is achievable by considering their different physicochemical properties, such as differences in solubility; free enantiomers can be released from the pure diastereomer salt or derivative by the action of a suitable agent. Optically active acids commonly used for this purpose and optically active alcohols applicable as auxiliary residues are known to those skilled in the art.

[0072] As described above, the compound of formula (I) can be converted to a salt, and in particular for pharmaceutical use, a pharmaceutically acceptable salt. As used herein, “pharmaceutically acceptable salt” means a derivative of the disclosed compound in which the parent compound has been modified by forming a pharmaceutically acceptable acid or base salt thereof. In this specification, the expression “pharmaceutically acceptable” means a compound, substance, composition, and / or dosage form that, within the bounds of reasonable medical judgment, is suitable for use in contact with human and animal tissues without excessive toxicity, irritation, allergic reactions, or other problems or complications, and which is balanced by a reasonable benefit / risk ratio. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali salts or organic salts of acidic residues such as carboxylic acids. For example, the salts include salts derived from benzenesulfonic acid, benzoic acid, citric acid, ethanesulfonic acid, fumaric acid, gentisic acid, hydrobromic acid, hydrochloric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, 4-methyl-benzenesulfonic acid, phosphoric acid, salicylic acid, succinic acid, sulfuric acid and tartaric acid. Cations from ammonia, L-arginine, calcium, 2,2'-iminobisethanol, L-lysine, magnesium, N-methyl-D-glucamine, potassium, sodium and tris(hydroxymethyl)-aminomethane can be used to form further pharmaceutically acceptable salts. The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compounds containing basic or acidic moieties by conventional chemical methods. Generally, the salts can be prepared by reacting the free acid or free base forms of these compounds with a sufficient amount of a suitable base or acid in water or an organic diluent such as ether, ethyl acetate, ethanol, isopropanol, or acetonitrile, or a mixture thereof. Salts of other acids (e.g., trifluoroacetate) useful for the purification or isolation of the compounds of the present invention, other than those described above, also form part of the present invention. The compounds of the present invention can also be advantageously obtained using the methods described in the following examples and, for this purpose, may be used in combination with methods known to those skilled in the art from the literature.

[0073] General technical considerations The terms "ambient temperature" and "room temperature" are used interchangeably to designate a temperature of about 20 °C, for example 15 - 25 °C. In principle, for the prepared compounds 1 1H NMR spectra and / or mass spectra were obtained. Unless otherwise specified, all chromatographic operations were carried out at room temperature.

[0074] Synthesis of intermediates Intermediate 1.1.I N-(2-Cyano-1-benzofuran-3-yl)-2,2,2-trifluoroacetamide

Chemical formula

[0075] TFAA (5.31 g, 25.3 mmol) was added by RT to a mixture of 3-amino-1-benzofuran-2-carbonitride (4.00 g, 25.3 mmol) in pyridine (40.0 mL). The mixture was stirred at 25°C for 12 hours, then concentrated under reduced pressure, diluted with 20 mL of water, and extracted with ethyl acetate. The mixed organic layers were washed with brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel; PE / ethyl acetate = 20 / 1 → 5 / 1). ESI-MS: 254.9 [M+H] + R t (HPLC): 0.56 min (Method A)

[0076] The following intermediates were prepared according to the general procedure described above (Intermediate 1.1.I). [ka]

[0077] Intermediate 1.1.III N-(2-cyano-1-benzofuran-3-yl)-2,2-difluoropropanamide [ka]

[0078] HATU (1.04 g, 2.73 mmol), followed by 3-amino-1-benzofuran-2-carbonitrile (474 ​​mg, 3.00 mmol), was added to a mixture of 2,2-difluoropropionic acid (300 mg, 2.73 mmol) and DIPEA (1.41 mL, 8.18 mmol) in 2.00 mL of DMF at RT. The reaction was stirred at RT for 1.5 hours, after which a mixture of 2,2-difluoropropionic acid (300 mg, 2.73 mmol), DIPEA (1.41 mL, 8.18 mmol), and HATU (1.04 g, 2.73 mmol) in 2.0 mL was added to the reaction mixture and stirring was continued. DCM and water were added to the reaction mixture and the product was extracted. The phases were separated and concentrated under vacuum, and the crude product was purified by RP-HPLC (X-Bridge C18, ACN / H2O / TFA). ESI-MS: 249 [MH] - R t (HPLC): 0.53 min (Method A)

[0079] Intermediate 1.2.I 6-Chloro-4-(trifluoromethyl)-8-oxa-3,5-diazatricyclo[7.4.0.0 2,7 ]Trideca-1(9),2(7),3,5,10,12-hexaene [ka]

[0080] To a solution of N-(2-cyano-1-benzofuran-3-yl)-2,2,2-trifluoroacetamide (intermediate 1.1.I, 4.00 g, 15.7 mmol) in sulfolane (10.0 mL), phosphorus pentachloride (13.1 g, 63.0 mmol) was added. The mixture was stirred at 110 °C for 16 hours. The reaction mixture was poured into ice water and extracted with ethyl acetate. The mixed organic layers were washed with brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel; PE / ethyl acetate = 20 / 1 → 10 / 1). ESI-MS:273 [M+H] + Rt (HPLC): 0.71 min (Method A)

[0081] The following compounds were prepared according to the general procedure described above (intermediate 1.2.I). [ka]

[0082] Intermediate 1.3.I (2S,4S)-4-hydroxy-1-[4-(trifluoromethyl)-8-oxa-3,5-diazatricyclo[7.4.0.0 2,7 ]-Trideca-1(9),2(7),3,5,10,12-Hexaen-6-yl]pyrrolidine-2-carboxylic acid [ka]

[0083] A mixture of (2S,4S)-4-hydroxypyrrolidine-2-carboxylic acid (1.44 g, 11.0 mmol) preheated at 110°C in DMSO (25.0 mL) is mixed with DIPEA (3.90 g, 30.0 mmol) and 6-chloro-4-(trifluoromethyl)-8-oxa-3,5-diazatricyclo[7.4.0.0 2,7 Trideca-1(9),2(7),3,5,10,12-hexaene (intermediate 1.2.I, 2.73 g, 10.0 mmol) was added. After stirring at 110°C for 10 minutes, the reaction mixture was added dropwise to water and acidified with 4 M HCl. The precipitate was filtered and dried. ESI-MS:368 [M+H] + R t (HPLC): 0.50 min (Method A)

[0084] The following compounds were prepared according to the general procedure described above (intermediate 1.3.I). [ka] [ka]

[0085] Intermediate 2.1 3-(1-nitroethyl)oxetan-3-ol [ka]

[0086] A mixture of nitroethane (27.3 g, 364 mmol) in 50 mL of methanol was cooled to 0°C. Under cooling, TEA (9.74 mL, 69.4 mmol) was added dropwise, followed by the dropwise addition of oxetane-3-one (25.0 g, 347 mmol). Cooling was stopped, and the reaction mixture was stirred at RT for 1 hour before being concentrated. The residue was purified by column chromatography (silica gel; CH / Â=75 / 25 → 50 / 50). ESI-MS: r 146 [MH] - R t (EI): 3.38 minutes

[0087] Intermediate 2.2 3-(1-aminoethyl)oxetane-3-ol [ka]

[0088] A mixture of 3-(1-nitroethyl)oxetan-3-ol (intermediate 2.1, 24.5 g, 157 mmol), 280 mL of ethanol, and Pd(OH)2 / C 5 mol% (5.52 g, 7.87 mmol) is heated in a Parr apparatus under a hydrogen pressure of 50 psi (3.4 × 10⁻¹⁰). 5 The mixture was left under reduced pressure for 16 hours. The reaction mixture was filtered, concentrated under reduced pressure, and used in the next step without further purification. ESI-MS:118 [M+H] + R f (TLC): 0.20 (PE / siRNA = 0 / 1)

[0089] Intermediate 2.3 2-Chloro-N-[1-(3-hydroxyoxetan-3-yl)ethyl]acetamide [ka]

[0090] A mixture of 3-(1-aminoethyl)oxetan-3-ol (intermediate 2.2, 32.4 g, 262 mmol) in 500 mL of ACN was cooled to 0°C, TEA (44.2 mL, 315 mmol) was added, and then chloroacetyl chloride (23.0 mL, 289 mmol) was added dropwise. The mixture was returned to RT and stirred for 3 hours. The precipitate was removed by filtration, and the filtrate was diluted with 50 mL of methanol and concentrated under vacuum. The residue was purified by column chromatography (silica gel; DCM / methanol = 97 / 3 → 85 / 15). ESI-MS:194 [M+H] + R t (HPLC): 0.27 min (Method E)

[0091] The following compounds were prepared according to the general procedure described above (intermediate 2.3). [ka]

[0092] Intermediate 2.4 9-methyl-2,5-dioxa-8-azaspiro[3.5]nonane-7-one [ka]

[0093] Under argon light at RT, a degassed solution of 2-chloro-N-[1-(3-hydroxyoxetan-3-yl)ethyl]acetamide (intermediate 2.3, 1.24 g, 6.02 mmol) in 24.0 mL of tert-amyl alcohol was added dropwise to a stirred degassed solution of potassium tert-butoxide (1.01 g, 9.03 mmol) in 12.0 mL of tert-amyl alcohol within 30 minutes. After the addition was complete, the reaction mixture was stirred at RT for a further 1 hour. Next, MeOH (5.0 mL) and water (0.5 mL) were added, and the mixture was stirred at RT for 20 minutes. After evaporation of volatile substances, the residue was transferred to DCM and purified by column chromatography (silica gel; DCM / methanol = 99 / 1 → 90 / 10). ESI-MS:158 [M+H] + R t (HPLC): 0.24 min (Method E)

[0094] The following compounds were prepared according to the general procedure described above (intermediate 2.4). [ka]

[0095] Intermediate 2.5 9-methyl-2,5-dioxa-8-azaspiro[3.5]nonane [ka]

[0096] Under argon, while maintaining the temperature below 0°C, a 1.0 M solution of LiAlH4 in diethyl ether was added dropwise to a degassed mixture of 9-methyl-2,5-dioxa-8-azaspiro[3.5]nonane-7-one (intermediate 2.4, 3.80 g, 23.0 mmol) in 90.0 mL of THF. After the addition was complete, the reaction mixture was heated to RT and stirred at this temperature for a further 16 hours. The reaction mixture was cooled to 0°C, diluted with 60 mL of anhydrous diethyl ether, and subsequently treated with 1.33 mL of water, 1.33 mL of 4N NaOH aqueous solution, and finally with 4 mL of water. The reaction mixture was allowed to return to room temperature and stirred for a further 15 minutes. The mixture was dried over sodium sulfate and then filtered, and the solvent was evaporated under vacuum. The residual residue was evaporated twice simultaneously with ACN to remove residual water. ESI-MS:144 [M+H] + R t (HPLC): 0.17 min (Method E)

[0097] The following compounds were prepared according to the general procedure described above (intermediate 2.5). [ka]

[0098] Intermediate 2.6.I 8-(5-bromo-2-nitropyridine-3-yl)-9-methyl-2,5-dioxa-8-azaspiro[3.5]nonane [ka]

[0099] To a mixture of 5-bromo-3-fluoro-2-nitropyridine (1.00 g, 4.53 mmol) in 20.0 mL of ACN, K2CO3 (1.88 g, 13.58 mmol) and 9-methyl-2,5-dioxa-8-azaspiro[3.5]-nonane (intermediate 2.5 g, 777 mg, 5.43 mmol) were added. The mixture was heated to 60°C and stirred for 16.5 hours. The reaction was diluted with ELISA and water was added. The phases were separated, and the aqueous phase was extracted with ELISA. The combined organic phase was dried over Na2SO4 and concentrated. ESI-MS:344 / 346 [M+H] + R t (HPLC): 0.85 min (Method B)

[0100] The following compounds were prepared according to the general procedure described above (intermediate 2.6.I). [ka] [ka] [ka]

[0101] Intermediate 2.7.I 9-Methyl-8-(2-nitro-5-{2-[tris(propan-2-yl)silyl]ethynyl}pyridine-3-yl)-2,5-dioxa-8-azaspiro[3.5]nonane [ka]

[0102] Under argon conditions, a degassed solution of 8-(5-bromo-2-nitropyridine-3-yl)-9-methyl-2,5-dioxa-8-azaspiro[3.5]nonane (intermediate 2.6.I, 584 mg, 1.70 mmol) in 6.80 mL of THF was mixed with DIPEA (2.31 mL, 12.8 mmol), followed by (triisopropylsilyl)-acetylene (0.780 mL, 3.40 mmol), PdCl2(PPh3)2 (60 mg, 0.085 mmol), and copper(I) iodide (49 mg, 0.25 mmol). The mixture was stirred at 80°C for 1 hour. The reaction mixture was diluted with ACN, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel; CH / Â=50 / 50 → 60 / 40). ESI-MS:446 [M+H] + R t (HPLC): 0.66 min (Method G)

[0103] The following compounds were prepared according to the general procedure described above (intermediate 2.7.I). [ka]

[0104] Intermediate 3.1.I(a) (a): (2S,4S)-4-({5-bromo-3-[(9S)-9-methyl-2,5-dioxa-8-azaspiro[3.5]nonan-8-yl]pyridine-2-yl}oxy)-1-[4-(difluoromethyl)-8-oxa-3,5-diazatricyclo[7.4.0.02,7]-trideca-1(9),2(7),3,5,10,12-hexaen-6-yl]pyrrolidine-2-carboxylic acid [ka]

[0105] (2S,4S)-1-[4-(difluoromethyl)-8-oxa-3,5-diazatricyclo[7.4.0.0] in 20 mL of DMA at RT. 2,7 NaH (326 mg, 8.16 mmol) was added to a mixture of ]-trideca-1(9),2(7),3,5,10,12-hexaen-6-yl]-4-hydroxypyrrolidine-2-carboxylic acid (intermediate 1.3.II, 1.00 g, 2.72 mmol) and 8-(5-bromo-2-nitropyridine-3-yl)-9-methyl-2,5-dioxa-8-azaspiro[3.5]nonane (intermediate 2.6.I, 2.00 g, 5.44 mmol). The mixture was stirred overnight in RT. Water was added and the mixture was acidified with TFA. The precipitate was collected by filtration and dried in vacuum. The crude product was purified by RP-HPLC (Sunfire C18, ACN / H2O / TFA) to obtain two diastereomers, (a) and (b). Diastereomer (a) was carried over to the next step. ESI-MS:646 / 648 [M+H] + R t (HPLC): 1.03 min (Method C) - Diastereomer (a) 1.08 min (Method C) - Diastereomer (b)

[0106] The following compounds were prepared according to the general procedure described above (intermediate 3.1.I). [ka]

[0107] Intermediate 3.2 (2S,4S)-4-({5-bromo-3-[(9S)-9-methyl-2,5-dioxa-8-azaspiro[3.5]nonan-8-yl]pyridine-2-yl}oxy)-1-[4-(difluoromethyl)-8-oxa-3,5-diazatricyclo[7.4.0.0 2,7 ]-Trideca-1(9),2(7),3,5,10,12-Hexaen-6-yl]pyrrolidine-2-carboxylate tert-butyl [ka]

[0108] (2S,4S)-4-({5-bromo-3-[(9S)-9-methyl-2,5-dioxa-8-azaspiro[3.5]nonan-8-yl]pyridine-2-yl}oxy)-1-[4-(difluoromethyl)-8-oxa-3,5-diazatricyclo[7.4.0.0 2,7 2-tert-butyl-1,3-disopropylisourea (162 μL, 0.68 mmol) was added to trideca-1(9),2(7),3,5,10,12-hexaen-6-yl]pyrrolidine-2-carboxylic acid (intermediate 3.1.I(a), 110 mg, 0.170 mmol). The reaction mixture was stirred in a microwave oven at 70°C for 1 hour. The precipitate was filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel; CH / Â=93 / 7 → 60 / 40). ESI-MS:702 / 704 [M+H] + R t (HPLC): 0.87 min (Method A)

[0109] Intermediate 3.3 (2S,4S)-1-[4-(difluoromethyl)-8-oxa-3,5-diazatricyclo[7.4.0.0 2,7]-Trideca-1(9),2(7),3,5,10,12-Hexaen-6-yl]-4-({3-[(9S)-9-methyl-2,5-dioxa-8-azaspiro[3.5]nonanane-8-yl]-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine-2-yl}oxy)pyrrolidine-2-carboxylate tert-butyl [ka]

[0110] (2S,4S)-4-({5-bromo-3-[(9S)-9-methyl-2,5-dioxa-8-azaspiro[3.5]nonan-8-yl]pyridine-2-yl}oxy)-1-[4-(difluoromethyl)-8-oxa-3,5-diazatricyclo[7.4.0.0] in 2.00 mL of dioxane under argon. 2,7 Trideca-1(9),2(7),3,5,10,12-hexaen-6-yl]pyrrolidine-2-carboxylate tert-butyl (intermediate 3.2 mg, 132 mg, 0.150 mmol) was mixed with bis(pinacolato)-diboron (113 mg, 0.445 mmol), Pd(dppf)Cl2 (12.0 mg, 0.0160 mmol), and potassium acetate (58.0 mg, 0.591 mmol). The reaction mixture was stirred overnight at 90°C. The reaction mixture was diluted with water and extracted with DCM / methanol. The organic phase was processed using an ISOLUTE® phase separator and concentrated under reduced pressure. ESI-MS:750 [M+H] + R t (HPLC): 0.90 min (Method A)

[0111] Intermediate 3.4.I (2S,4S)-1-[4-(difluoromethyl)-8-oxa-3,5-diazatricyclo[7.4.0.0 2,7]trideca-1(9),2(7),3,5,10,12-hexaen-6-yl]-4-({N,N-dimethyl-5-[(9S)-9-methyl-2,5-dioxa-8-azaspiro[3.5]nonan-8-yl]-[3,4'-bipyridine]-2'-yl}oxy)pyrrolidine-2-carboxylate tert-butyl [ka]

[0112] (2S,4S)-1-[4-(difluoromethyl)-8-oxa-3,5-diazatricyclo[7.4.0.0] in 2.00 mL of dioxane under argon. 2,7 ]trideca-1(9),2(7),3,5,10,12-hexaen-6-yl]-4-({3-[(9S)-9-methyl-2,5-dioxa-8-azaspiro[3.5]nonan-8-yl]-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine-2-yl}oxy)pyrrolidine-2-carboxylate tert-butyl (intermediate 3.3 mg, 105 mg, 0.0700 mmol) with 4-bromo-N,N-dimethylpyridine-2-amine (22.0 mg, 0.109 mmol), Pd(PPh3)4 (9.7 mg, 0.0080 mmol), Xphos 3 rd Gen (6.0 mg, 0.0070 mmol) and 2 mol / L sodium carbonate solution (105 μL, 0.210 mmol) were added. The reaction mixture was stirred at 100°C for 1.5 hours. The reaction mixture was diluted with ACN / water, filtered, and purified by RP-HPLC (Xbridge-C18, ACN / H2O / 0.1% NH4OH). ESI-MS:744 [M+H] + R t (HPLC): 0.64 min (Method A)

[0113] The following compounds were prepared according to the general procedure described above (intermediate 3.4.I). [ka]

[0114] Intermediate 4.1 4-Bromo-3-methoxy-N,N-dimethylpyridine-2-amine [ka]

[0115] Dimethylamine (3.64 mL, 7.28 mmol) was added to 4-bromo-2-fluoro-3-methoxypyridine (200 mg, 0.97 mmol) in 3.00 mL of THF. The reaction mixture was stirred overnight at 50°C and then concentrated under reduced pressure to obtain the title compound. ESI-MS:231 / 233 [M+H] + R t (HPLC): 0.30 min (Method A)

[0116] Intermediate 5.1 4-iodo-3-methoxy-N-methylpyridine-2-amine [ka]

[0117] 500 mg (1.98 mmol) of 2-fluoro-4-iodo-3-methoxypyridine in 8.00 mL of THF was mixed with a 2.0 M solution of methylamine in THF (7.90 mL, 15.8 mmol). The reaction mixture was stirred at 55°C for 48 hours and then concentrated under reduced pressure. ESI-MS:265 [M+H] + R t (HPLC): 0.26 min (Method A)

[0118] Intermediate 6.1 8-(2,5-difluoropyridine-3-yl)-9-methyl-2,5-dioxa-8-azaspiro[3.5]nonane [ka]

[0119] Under an argon atmosphere, a degassed solution of 8-(5-bromo-2-fluoropyridine-3-yl)-9-methyl-2,5-dioxa-8-azaspiro[3.5]nonane (intermediate 7.1.III, 668 mg; 2.00 mmol) in THF (13.4 mL) was cooled to 0°C. Next, a solution of isopropylmagnesium chloride-lithium chloride complex in THF (1.92 mL; 2.5 mmol) was added dropwise. The reaction mixture was allowed to return to room temperature and stirred for 2.5 hours. Additional isopropylmagnesium chloride-lithium chloride complex in THF (0.45 mL; 0.59 mmol) was added and stirring continued for a further 1.5 hours. The mixture was concentrated under vacuum and then transferred to DCM (5.00 mL) and cooled to -78°C. A solution of N-fluorobenzenesulfonamide (863 mg, 2.60 mmol) in a mixture of DCM (7.50 mL) and perfluorodecalin (2.50 mL) was added dropwise while stirring at -78°C. After the addition was complete, the reaction mixture was warmed to 0°C, stirred for 30 minutes, then warmed to RT and stirred for another hour. The reaction mixture was poured into a saturated NH4Cl solution and stirred for 5 minutes. The mixture was filtered through Celite, and after phase separation, the aqueous phase was extracted with DCM. The mixed organic phase was dried over sodium sulfate, filtered, and evaporated. The residue was dissolved in ACN / H2O, filtered, and purified by RP-HPLC. ESI-MS:257 [M+H] + R t (HPLC): 0.45 min (Method A)

[0120] Intermediate 7.1.I 5-Chloro-2-fluoro-3-{4H,5H,6H,7H-[1,2]oxazolo[4,3-c]pyridine-5-yl}pyridine [ka]

[0121] 5-chloro-2-nitro-3-{4H,5H,6H,7H-[1,2]oxazolo[4,3-c]pyridine-5-yl}pyridine (intermediate 2.6.VII, 210 mg, 0.750 mmol) was added to 2.00 mL of DMF with a 1.0 M solution of TBAF in THF (1.50 mL, 1.50 mmol). The reaction mixture was stirred at RT for 30 minutes, then stirred at 50°C for 3 hours. TBAF was added again (1.50 mL, 1.50 mmol), and the reaction mixture was stirred at 50°C for 5 hours. ACN / water was added to the reaction mixture, the precipitate was collected by filtration, and purified by RP-HPLC (Xbridge C18, ACN / H2O / TFA). ESI-MS:254 / 256 [M+H] + R t (HPLC): 0.77 min (Method E)

[0122] The following compounds were prepared according to the general procedure described above (intermediate 7.1.I). [ka]

[0123] Intermediate 8.1 (2S,4S)-4-{[5-ethynyl-3-(morpholine-4-yl)pyridine-2-yl]oxy}pyrrolidine-2-carboxylic acid [ka]

[0124] (2S,4S)-1-(tert-butoxycarbonyl)-4-hydroxypyrrolidine-2-carboxylic acid (202 mg, 0.83 mmol) was added to 3.00 mL of DMA with NaH (99.8 mg, 2.50 mmol). After stirring the mixture in RT for 30 minutes, a solution of 4-{2-nitro-5-[2-(trimethylsilyl)ethynyl]-pyridine-3-yl}morpholine (intermediate 2.7.II, 127 mg, 0.42 mmol) in 2.00 mL of DMA was added. The reaction mixture was stirred in RT for 2 hours, then diluted with ACN and acidified with TFA. The precipitate was collected by filtration and purified by RP-HPLC (Sunfire, ACN / H2O / TFA). The residue was diluted with 10.0 mL of DCM and 1.00 mL of TFA was added. The reaction mixture was stirred overnight in RT and concentrated to obtain the title compound. ESI-MS:318 [M+H] + R t (HPLC): 0.67 min (Method C)

[0125] Intermediate 9.1(a) (2S,4S)-1-[(tert-butoxy)carbonyl]-4-({5-ethynyl-3-[(9S)-9-methyl-2,5-dioxa-8-azaspiro[3.5]nonan-8-yl]pyridine-2-yl}oxy)pyrrolidine-2-carboxylic acid [ka]

[0126] NaH (660 mg, 16.5 mmol) was added to a mixture of (2S,4S)-1-[(tert-butoxy)carbonyl]-4-hydroxypyrrolidine-2-carboxylic acid (800 mg, 3.30 mmol) and 9-methyl-8-(2-nitro-5-{2-[tris(propan-2-yl)silyl]ethynyl}pyridine-3-yl)-2,5-dioxa-8-azaspiro[3.5]nonane (intermediate 2.7.I, 1.55 g, 3.30 mmol) in 31.0 mL of NMP. The reaction mixture was stirred at RT for 1 hour and 20 minutes. The reaction mixture was quenched with water, acidified with 1N HCl, filtered, and extracted three times with RINKAN. The organic phases were mixed, dried over sodium sulfate, filtered, and evaporated. The crude product was dissolved in 10 mL of THF, and 2 mL of TBAF solution (1.0 M in THF) was added. The reaction mixture was stirred at 50°C for 1 hour. The reaction mixture was diluted with  and extracted twice with saturated NH4Cl solution. The organic phases were mixed, dried over sodium sulfate, filtered, and evaporated. The residue was purified by HPLC (Xbridge, ACN / H2O / TFA). ESI-MS:474 [M+H] + R t (HPLC): 0.63 min (Method A) - Diastereomer (a) 0.66 min (Method A) - diastereomer (b)

[0127] Intermediate 9.2 (2S,4S)-4-({5-ethynyl-3-[(9S)-9-methyl-2,5-dioxa-8-azaspiro[3.5]nonan-8-yl]pyridine-2-yl}oxy)pyrrolidine-2-carboxylic acid [ka]

[0128] (2S,4S)-1-[(tert-butoxy)carbonyl]-4-({5-ethynyl-3-[(9S)-9-methyl-2,5-dioxa-8-azaspiro[3.5]nonane-8-yl]pyridine-2-yl}oxy)pyrrolidine-2-carboxylic acid (intermediate 9.1(a), 40 mg, 0.080 mmol) was added to 3.00 mL of ACN with TosOH (35 mg, 0.18 mmol). The reaction mixture was stirred at RT for 48 hours. The reaction mixture was evaporated and used in the next step without further purification. ESI-MS:374 [M+H] + R t (HPLC): 0.36 min (Method A)

[0129] Intermediate 10.1 4-(difluoromethyl)-2-methoxybenzonitrile [ka]

[0130] To 3.00 mL of DCM containing 4-formyl-2-methoxybenzonitrile (806 mg, 5.00 mmol), bis(2-methoxyethyl)aminosulfate trifluoride (50% solution in toluene, 3.13 mL, 8.50 mmol) and ethanol (1.00 mmol, 57.6 μL) were slowly added. The reaction mixture was stirred overnight in RT. Again, bis(2-methoxyethyl)aminosulfate trifluoride (920 μL, 2.5 mmol) was added, followed by ethanol (20.0 μL, 0.5 mmol). This mixture was stirred in RT for 1 hour, then poured over a saturated aqueous solution of NaHCO3 and stirred for 5 minutes. The phases were separated, and the aqueous phase was extracted with DCM. The organic phases were mixed, washed with water, dried, and evaporated. The crude product was used directly in the next step. R t (HPLC): 0.49 min (Method A)

[0131] Intermediate 10.2 4-(difluoromethyl)-2-hydroxybenzonitrile [ka]

[0132] A mixture of 2-(diethylamino)ethanethiol (300 mg, 1.77 mmol) in 3.00 mL of DMF was cooled to 0°C, and sodium tert-butoxide (340 mg, 3.54 mmol) was added. The reaction mixture was stirred at 0°C for 5 minutes. The cooling bath was then removed, and the mixture was returned to RT. A solution of 4-(difluoromethyl)-2-methoxybenzonitrile (intermediate 10.1 mg, 50.0 mg, 0.270 mmol) in 2.00 mL of DMF was added at RT, and the resulting mixture was heated at 160°C for 1.5 hours with stirring. The reaction mixture was then cooled to 0°C and acidified with 1N HCl aqueous solution. The reaction mixture was extracted with ethyl acetate, and the mixed organic layers were dried and evaporated. The crude product was purified by RP-HPLC (Xbridge, ACN / H2O / TFA). ESI-MS:170 [M+H] + R t (HPLC): 0.41 min (Method A)

[0133] Intermediate 10.3.I 3-amino-6-(difluoromethyl)-1-benzofuran-2-carboxamide [ka]

[0134] 4-(difluoromethyl)-2-hydroxybenzonitrile (intermediate 10.2 mg, 120 mg, 0.71 mmol) was added to 5.00 mL of ethanol with K2CO3 (150 mg, 1.09 mmol) and 2-bromoacetamide (119 mg, 0.87 mmol). The reaction mixture was heated and refluxed for 2 hours. The reaction mixture was returned to RT and KOH (95.1 mg, 1.44 mmol) was added. Next, the mixture was heated and refluxed for 2 hours. After cooling to RT, the reaction mixture was diluted with water. The ethanol was evaporated under vacuum, the precipitate was collected by filtration, washed with water, and dried. ESI-MS:227 [M+H] + R t (HPLC): 0.39 min (Method A)

[0135] The following compounds were prepared according to the general procedure described above (intermediate 10.3.I). [ka]

[0136] Intermediate 10.4.I 6-Chloro-11-(difluoromethyl)-4-methyl-8-oxa-3,5-diazatricyclo[7.4.0.0 2,7 ]Trideca-1(9),2(7),3,5,10,12-hexaene [ka]

[0137] Under an argon atmosphere at 0°C, a mixture of phosphorus oxychloride (92.0 μL, 1.01 mmol) and DMA (39.0 μL, 0.40 mmol) was stirred for 30 minutes. This mixture was diluted with 0.5 mL of phosphorus oxychloride and then added dropwise to 3-amino-6-(difluoromethyl)-1-benzofuran-2-carboxamide (intermediate 10.3.I, 76.0 mg, 0.34 mmol). After the addition was complete, the mixture was heated to 50°C and stirred for 3 hours. Again, phosphorus oxychloride (184 μL, 2.02 mmol) was added, and the reaction mixture was stirred overnight at 50°C. The reaction mixture was cooled to RT, diluted with ice water, and neutralized with aqueous NaHCO3 solution. The mixture was extracted with DCM, the organic phase was dried, filtered, and evaporated. ESI-MS:269 [M+H] + R t (HPLC): 0.62 min (Method A)

[0138] The following compounds were prepared according to the general procedure described above (intermediate 10.4.I). [ka]

[0139] Intermediate 11.1 (2S)-1-(5-bromo-2-nitropyridine-3-yl)-2-methylpiperazine [ka]

[0140] 5-bromo-3-fluoro-2-nitropyridine (200 mg, 0.91 mmol) in 4.00 mL of ACN was mixed with (3S)-3-methylpiperazine-1-carboxylate tert-butyl (272 mg, 1.36 mmol) and TEA (635 μL, 4.53 mmol). The reaction mixture was stirred at 80°C for 2.75 hours. The reaction mixture was quenched with RINKAN and extracted with NH₄Cl semisaturated solution, NaHCO₃ semisaturated solution, and NaCl saturated solution. The organic phase was dried, filtered, and concentrated. The residue was diluted in 4N HCl in dioxane, stirred at RT for 45 minutes, and concentrated to obtain the title compound as a salt. ESI-MS:301 / 303 [M+H] + R t (HPLC): 0.70 min (Method C)

[0141] Intermediate 11.2 (3S)-4-(5-bromo-2-nitropyridine-3-yl)-3-methylpiperazine-1-carbonitrile [ka]

[0142] (2S)-1-(5-bromo-2-nitropyridine-3-yl)-2-methylpiperazine hydrochloride (intermediate 11.1 mg, 80.0 mg, 0.24 mmol) in 2.00 mL of DCM was mixed with DIPEA (103 μL, 0.592 mmol) and cyanogen bromide (3 mol / L in DCM, 86.9 μL, 0.261 mmol). The reaction mixture was stirred overnight in RT. Cyanogen bromide (3 mol / L in DCM, 86.9 μL, 0.261 mmol) was added to the reaction mixture again and stirred in RT for 1 hour. The reaction mixture was quenched with a semisaturated aqueous solution of NaHCO3. The phases were separated and extracted with DCM. The mixed organic phases were dried by passing them through an ISOLUTE® phase separator and evaporated. ESI-MS:326 / 328 [M+H] + R t (HPLC): 0.83 min (Method C)

[0143] Intermediate 12.1 (5S)-5-methyl-1,2,6-triazaspiro[2.5]octa-1-ene-6-carboxylate tert-butyl [ka]

[0144] At 0°C, 6.70 mL of ammonia (7N in methanol) was added to (2S)-2-methyl-4-oxopiperidine-1-carboxylate tert-butyl (1.00 g, 4.69 mmol). The reaction mixture was stirred and returned to RT overnight. The mixture was then cooled to -20°C, and hydroxylamine-O-sulfonic acid (1.33 g, 11.7 mmol) was added gradually. The reaction mixture was returned to RT and stirred for 1 hour. The precipitate was filtered off, washed with methanol, and the filtrate was concentrated under vacuum. The concentrate was taken in ELISA (20 mL / 72 mL) and extracted with 10% Na2CO3 aqueous solution (15 mL). The organic phase was extracted with water and dried through an ISOLUTE® phase separator. The organic layer was diluted with 10 mL of methanol and cooled to -10°C. Iodine (1.31 g, 5.16 mmol) was added, and the reaction mixture was returned to RT. The reaction mixture was quenched with a 5% sodium sulfite solution and extracted with a 10% aqueous NaCl solution. The organic phase was dried over Na2SO4, filtered, and evaporated. The product was purified by HPLC (Sunfire, ACN / H2O / TFA). ESI-MS:248 [M+Na] + R t (HPLC): 1.09 min (Method C)

[0145] Intermediate 12.2 (5S)-5-methyl-1,2,6-triazaspiro[2.5]octa-1-ene [ka]

[0146] (5S)-5-methyl-1,2,6-triazaspiro[2.5]octa-1-ene-6-carboxylate tert-butyl (intermediate 12.1 mg, 440 mg, 1.95 mmol) was added to 5.00 mL of DCM with TFA (0.50 mL, 3.00 mmol). The reaction mixture was stirred at RT for 6 hours, then concentrated and used in the next step without further purification. ESI-MS:126 [M+H] + R t (HPLC): 0.11 min (Method C)

[0147] Intermediate 13.1 2-Methylpiperidine-3-carboxylate methyl acetate [ka]

[0148] 10.0 g of methyl 2-methylpyridine-3-carboxylate (66.2 mmol) was added to 80.0 mL of acetic acid, and the mixture was hydrogenated at 80°C under 3 bar for 12 hours. The reaction mixture was filtered, concentrated under reduced pressure, and used in the next step without further purification. ESI-MS:158 [M+H] + R t (HPLC): 0.27 min (Method N)

[0149] Intermediate 13.2 2-methylpiperidine-1,3-dicarboxylic acid 1-tert-butyl 3-methyl [ka]

[0150] To 90.0 mL of THF, methyl 2-methylpiperidine-3-carboxylate (intermediate 13.1 g, 15.0 g, 60.4 mmol) was mixed with TEA (8.49 mL, 60.4 mmol) and di-tert-butyl dicarbonate (13.2 g, 60.4 mmol), and the reaction mixture was stirred at RT for 1.5 hours. The reaction mixture was diluted with ELISA and extracted with a semi-saturated NaHCO3 solution. The organic phase was dried over Na2SO4, filtered, and evaporated. The crude product was purified by column chromatography (silica gel; CH / ELISA = 99 / 1 → 1 / 99). ESI-MS:258 [M+H] + R t (HPLC): 0.65 min (Method F)

[0151] Intermediate 13.3 2-methylpiperidine-1,3,3-tricarboxylic acid 1-tert-butyl 3,3-dimethyl [ka]

[0152] A solution of 1-tert-butyl 3-methyl 2-methylpiperidine-1,3-dicarboxylic acid (intermediate 13.2 g, 18.5 mmol) in 20.0 mL of THF was added to a solution of lithium diisopropylamide (2 mol / L, 11.1 mL, 22.2 mmol) in 32.5 mL of THF under argon at -78°C. The reaction mixture was cooled to -20°C and stirred for 30 minutes. Next, the reaction mixture was cooled to -78°C, and a solution of methyl chloroformate (2.25 mL, 27.7 mmol) in 10.0 mL of THF was added dropwise to the reaction mixture. The temperature was maintained below -65°C during the addition. After the addition was complete, the reaction mixture was returned to RT and stirred at RT for 2 hours. The reaction mixture was quenched with a saturated NH4Cl solution and stirred at RT for 10 minutes. The mixture was diluted with water and extracted with DCM. The organic layers were mixed, dried over sodium sulfate, filtered, and concentrated under vacuum. The residue was purified by column chromatography (silica gel; CH / ا=95 / 5 → 60 / 40). ESI-MS:316 [M+H] + R f (TLC): 0.29 (CH / ا=20 / 80)

[0153] Intermediate 13.4 3,3-Bis(hydroxymethyl)-2-methylpiperidine-1-carboxylate tert-butyl [ka]

[0154] To a degassed solution of 1-tert-butyl 3,3-dimethyl 2-methylpiperidine-1,3,3-tricarboxylic acid (intermediate 13.3, 5.60 g, 16.9 mmol) in 44.8 mL of THF under argon, LiAlH4 (2.3 mol / L in 2-methyltetrahydrofuran, 14.6 mL, 33.7 mmol) was added dropwise, and the mixture was stirred at RT for 1.5 hours. The reaction mixture was cooled to 0°C, diluted in 80.0 mL of diethyl ether, and carefully treated with 1.25 mL of water, then 1.25 mL of 4N NaOH, and finally 3.75 mL of water. The reaction mixture was returned to RT and stirred for 15 minutes. The mixture was dried over Na2SO4, filtered, and evaporated. The residue was purified by column chromatography (silica gel; CH / Â=75 / 25 → 0 / 100). ESI-MS:260 [M+H] + R f (TLC): 0.14 (CH / ا=50 / 50)

[0155] Intermediate 13.5 5-methyl-2-oxa-6-azaspiro[3.5]nonane-6-carboxylate tert-butyl [ka]

[0156] Triphenylphosphine (525 mg, 2.00 mmol) was added to 3,3-bis(hydroxymethyl)-2-methylpiperidine-1-carboxylate tert-butyl (intermediate 13.4 mg, 259 mg, 1.00 mmol) in 6.00 mL of THF. The reaction mixture was stirred at RT for 5 minutes. Next, Ziram (483 mg, 1.50 mmol) and diisopropyl azodicarboxylic acid (413 μL, 2.00 mmol) were added, and the mixture was stirred at 70°C for 16 hours. The reaction mixture was diluted with Â, filtered through a Celite pad, and washed with Â. The filtrate was washed with 5% aqueous NH3 solution. The organic phase was dried, filtered, and evaporated. The residue was purified by column chromatography (silica gel; DCM / Â=95 / 5 → 70 / 30). The residue was purified by HPLC (Sunfire, ACN / H2O / TFA). ESI-MS:242 [M+H] + R t (HPLC): 0.80 min (Method E)

[0157] Intermediate 13.6 5-Methyl-2-oxa-6-azaspiro[3.5]nonane [ka]

[0158] 5-methyl-2-oxa-6-azaspiro[3.5]nonane-6-carboxylate tert-butyl (intermediate 13.5 mg, 0.56 mmol) was added to 2.00 mL of DCM with TFA (500 mL, 6.48 mmol). The reaction mixture was stirred at RT for 30 minutes, then concentrated under reduced pressure and used in the next step without further purification. ESI-MS:142 [M+H] + R t (HPLC): 0.17 min (Method E)

[0159] Intermediate 14.1 2-(cyanomethoxy)-4-ethylbenzonitrile [ka]

[0160] Bromoacetonitrile (1.22 mL, 17.5 mmol) was added to a mixture of 4-ethyl-2-hydroxybenzonitrile (2.34 g, 16.2 mmol) and potassium carbonate (4.83 g, 35.0 mmol) in 40.0 mL of DMF, and the reaction mixture was stirred overnight at 50°C. The reaction mixture was poured into water and extracted with DCM. The organic phase was concentrated under vacuum, and the crude product was used in the next step without further purification.

[0161] Intermediate 14.2 3-amino-6-ethyl-1-benzofuran-2-carbonitrile [ka]

[0162] Potassium tert-butoxide (108 mg, 0.964 mmol) was added to a mixture of 2-(cyanomethoxy)-4-ethylbenzonitrile (intermediate 14.1, 1.79 g, 10.0 mmol) in 40.0 mL of THF, and the mixture was stirred overnight under RT. The solvent was evaporated under vacuum, and the product was purified by column chromatography and used directly in the next step.

[0163] Intermediate 14.3 N-(2-cyano-6-ethyl-1-benzofuran-3-yl)-2,2,2-trifluoroacetamide [ka]

[0164] A mixture of 3-amino-6-ethyl-1-benzofuran-2-carbonitride (intermediate 14.2, 1.40 g, 7.51 mmol) in 20 mL of TFAA was stirred at 50°C for 3 hours. The solvent was evaporated to dryness under reduced pressure. The residue was transferred to ethyl acetate, the organic phase was washed with water, and the mixture was concentrated under vacuum. The crude product was used in the next step without further purification.

[0165] Intermediate 14.4 6-Chloro-11-ethyl-4-(trifluoromethyl)-8-oxa-3,5-diazatricyclo[7.4.0.0 2,7 ]Trideca-1(13),2,4,6,9,11-hexaene [ka]

[0166] A mixture of N-(2-cyano-6-ethyl-1-benzofuran-3-yl)-2,2,2-trifluoroacetamide (intermediate 14.3 g, 2.00 g, 7.09 mmol) in 5.0 mL of sulfolane was mixed with phosphorus pentachloride (5.90 g, 28.3 mmol) at 45°C. The mixture was stirred at 110°C for 16 hours, then poured onto ice water and extracted with ethyl acetate. The mixed organic layer was washed with brine and evaporated. The residue was purified by column chromatography (silica gel; CH / ethyl acetate = 100 / 0 → 95 / 5). ESI-MS:301 / 303 [M+H] + R t (HPLC): 0.79 min (Method A)

[0167] Intermediate 15.1 3-(2-chloroacetamide)-1-benzofuran-2-carboxamide [ka]

[0168] A mixture of 3-aminobenzofuran-2-carboxamide (3.52 g, 176 mmol) in chloroacetyl chloride (6.00 mL, 75 mmol) was stirred at 60°C for 10 minutes. Chloroacetyl chloride (4.00 mL, 50 mmol) was added and stirring was continued at 60°C for 20 minutes. The reaction mixture was poured onto ice water, the precipitate was collected by filtration, resuspended in water, filtered, and washed with water. The crude product was used directly in the next step without further purification. ESI-MS:253 [M+H]+ R t (HPLC): 0.41 min (Method A)

[0169] Intermediate 15.2 4-(hydroxymethyl)-8-oxa-3,5-diazatricyclo[7.4.0.02,7]trideca-1(9),2(7),3,10,12-pentaen-6-one [ka]

[0170] A mixture of 3-(2-chloroacetamide)-1-benzofuran-2-carboxamide (intermediate 15.1, 5.80 g, 23.0 mmol) in a 2M NaOH aqueous solution was stirred at 60°C for 10 minutes. After cooling to RT, stirring was continued for 10 hours, and then concentrated hydrochloric acid was added to adjust the pH to 1. The precipitate was collected by filtration, washed with water, and dried. ESI-MS:217 [M+H] + R t (HPLC): 0.59 min (Method C)

[0171] Intermediate 15.3 6-Chloro-4-(chloromethyl)-8-oxa-3,5-diazatricyclo[7.4.0.0 2,7 ]Trideca-1(9),2(7),3,5,10,12-hexaene [ka]

[0172] Phosphorus oxychloride (30 mL, 328 mmol) was added to 4-(hydroxymethyl)-8-oxa-3,5-diazatricyclo[7.4.0.02,7]trideca-1(9),2(7),3,10,12-pentaen-6-one (intermediate 15.2, 5.00 g, 17.3 mmol) under stirring, and the resulting mixture was heated and refluxed for 1.5 hours. The reaction mixture was cooled to RT and concentrated under vacuum. Ethyl acetate was added to the residue, and the mixture was neutralized by adding a saturated aqueous solution of sodium bicarbonate. The mixture was filtered on Celite to separate the phases, and the organic phase was dried on magnesium sulfate and evaporated. The crude product was purified by flash column chromatography (cyclohexane / siRNA = 88 / 12 → 0 / 100). ESI-MS:253 [M+H] + R t (HPLC): 1.07 min (Method C)

[0173] Intermediate 16.1 (2S,4S)-4-({3-[(9S)-9-methyl-2,5-dioxa-8-azaspiro[3.5]nonan-8-yl]-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine-2-yl}oxy)-1-[4-(trifluoromethyl)-8-oxa-3,5-diazatricyclo[7.4.0.0 2,7 ]-Trideca-1(9),2(7),3,5,10,12-Hexaen-6-yl]pyrrolidine-2-carboxylic acid [ka]

[0174] Under an argon atmosphere, a degassed mixture of Ex.1.10 (1.50 g, 2.26 mmol), bis-(pinacolato)-diboron (630 mg, 2.48 mmol), and potassium acetate (670 mg, 6.93 mmol) in 30 mL of dioxane was added to Pd(dppf)Cl2 (165 mg, 0.226 mmol). The reaction mixture was heated to 90°C for 3 hours, then cooled to RT, poured onto ice water, and extracted with diethyl ether / THF. The organic phases were mixed, dried over sodium sulfate, and concentrated under reduced pressure. The crude product was purified by flash column chromatography (siRNA / MeOH = 10:1). ESI-MS:712 [M+H] + R t (HPLC): 1.05 min (Method A)

[0175] Preparation of the final compound Example 1.01 (General Route) (2S,4S)-4-{[5-chloro-3-(2-cyanomorpholin-4-yl)pyridine-2-yl]oxy}-1-[4-(trifluoromethyl)-8-oxa-3,5-diazatricyclo[7.4.0.0 2,7 ]Trideca-1(13),2,4,6,9,11-hexaen-6-yl]pyrrolidine-2-carboxylic acid [ka]

[0176] (2S,4S)-4-hydroxy-1-[4-(trifluoromethyl)-8-oxa-3,5-diazatricyclo[7.4.0.0 2,7To trideca-1(9),2(7),3,5,10,12-hexaen-6-yl]pyrrolidine-2-carboxylic acid (intermediate 1.3.I, 58.0 mg, 0.15 mmol), 4-(5-chloro-2-nitropyridine-3-yl)morpholine-2-carbonitride (intermediate 2.6.III, 80.6 mg, 0.30 mmol, 2.0 equivalents) and NaH (18.0 mg, 0.45 mmol, 3.0 equivalents) were added. The reaction mixture was stirred at 80°C for 20 minutes. The reaction mixture was diluted with ACN / water, acidified with TFA, filtered, and purified by HPLC (ACN / H2O / TFA). The product was obtained as a mixture of two diastereomers. ESI-MS:589 [M+H] + R t (HPLC): 1.05 min (Method H)

[0177] The compounds listed in the table below were prepared according to the general procedure described above (Example 1.01). Where shown in the table, the compound examples were isolated as a diastereomer mixture (ds-mix) or as pure diastereomers (both isolated diastereomers (example) and the second diastereomer (2 nd (Rt is given for ds). [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] [Table 1-5] [Table 1-6] [Table 1-7] [Table 1-8] [Table 1-9]

[0178] The absolute stereochemistry of Example 1.10 was confirmed by low-molecular-weight X-rays as shown below. [ka]

[0179] The absolute stereochemistry of Example 1.28 was confirmed by low-molecular-weight X-rays as shown below. [ka]

[0180] Example 2.01 (General Route) (2S,4S)-1-[4-(difluoromethyl)-8-oxa-3,5-diazatricyclo[7.4.0.0 2,7 ]trideca-1(13),2,4,6,9,11-hexaen-6-yl]-4-{[5-ethynyl-3-(morpholine-4-yl)pyridine-2-yl]oxy}pyrrolidine-2-carboxylic acid [ka]

[0181] 6-chloro-4-(difluoromethyl)-8-oxa-3,5-diazatricyclo[7.4.0.0] in 1.50 mL of DMSO 2,7(2S,4S)-4-{[5-ethynyl-3-(morpholine-4-yl)pyridine-2-yl]oxy}pyrrolidine-2-carboxylic acid (intermediate 8.1, 55.9 mg, 0.13 mmol) and DIPEA (60.8 μL, 0.35 mmol) were added to trideca-1(9),2(7),3,5,10,12-hexaene (intermediate 1.2.II, 30.0 mg, 0.12 mmol). The reaction mixture was stirred at 110°C for 1 hour. The reaction mixture was diluted with ACN, acidified with TFA, filtered, and purified by HPLC (ACN / H2O / TFA). ESI-MS:536 [M+H] + R t (HPLC): 1.08 min (Method C)

[0182] The following example was prepared according to the general procedure described above (Example 2.1). [ka] [ka] [ka]

[0183] Example 3.01 (General Route) (2S,4S)-4-({5-[(3S)-3-methylmorpholine-4-yl]-[3,4'-bipyridine]-6-yl}oxy)-1-[4-(trifluoromethyl)-8-oxa-3,5-diazatricyclo[7.4.0.0 2,7 ]Trideca-1(9),2(7),3,5,10,12-hexaen-6-yl]pyrrolidine-2-carboxylic acid [ka]

[0184] (2S,4S)-4-({5-bromo-3-[(3S)-3-methylmorpholin-4-yl]pyridine-2-yl}oxy)-1-[4-(trifluoromethyl)-8-oxa-3,5-diazatricyclo[7.4.0.0 2,7 [Trideca-1(9),2(7),3,5,10,12-hexaen-6-yl]pyrrolidine-2-carboxylic acid (intermediate 3.1.II, 50.0 mg, 0.08 mmol), (pyridine-4-yl)boronic acid (24.7 mg, 0.20 mmol), Na2CO3 solution (2.0 M, 100 μL, 0.20 mmol), Xphos 3 rd A mixture of gen (3.40 mg) and Pd(PPh3)4 (4.64 mg) was mixed with 2.00 mL of dioxane under argon. The reaction mixture was stirred at 100°C for 2 hours. The reaction mixture was filtered, diluted with ACN / methanol, and purified by HPLC (Xbridge, ACN / H2O / TFA). ESI-MS:621 [M+H] + R t (HPLC): 0.818 min (Method B)

[0185] The following example was prepared according to the general procedure described above (Example 3.01). The boronate or boronic acid used is commercially available or can be easily prepared as described in the literature (Boronic Acids: Preparation and Applications in Organic Synthesis, Medicine and Materials, 1&2, 2). nd Edition, ISBN 9783527325986). [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka]

[0186] Example 4.01 (General Route) (2S,4S)-1-[4-(difluoromethyl)-8-oxa-3,5-diazatricyclo[7.4.0.0 2,7 ]trideca-1(9),2(7),3,5,10,12-hexaen-6-yl]-4-({N,N-dimethyl-5-[(9S)-9-methyl-2,5-dioxa-8-azaspiro[3.5]nonan-8-yl]-[3,4'-bipyridine]-2'-yl}oxy)pyrrolidine-2-carboxylic acid [ka]

[0187] (2S,4S)-1-[4-(difluoromethyl)-8-oxa-3,5-diazatricyclo[7.4.0.0] in 2.00 mL of DCM 2,7Trideca-1(9),2(7),3,5,10,12-hexaen-6-yl]-4-({N,N-dimethyl-5-[(9S)-9-methyl-2,5-dioxa-8-azaspiro[3.5]nonan-8-yl]-[3,4'-bipyridine]-2'-yl}oxy)pyrrolidine-2-carboxylate tert-butyl (intermediate 3.4.I, 13 mg, 0.020 mmol) was mixed with trifluoroacetic acid (650 μL, 8.49 mmol) over 1 day. The reaction mixture was stirred overnight in RT and then concentrated under reduced pressure. The crude product was purified by HPLC (Xbridge, ACN / H2O / TFA). ESI-MS:688 [M+H] + R t (HPLC): 0.51 min (Method A)

[0188] The following example was prepared according to the general procedure described above (Example 4.1). [ka]

[0189] Example 5.01 (2S,4S)-1-[4-(difluoromethyl)-8-oxa-3,5-diazatricyclo[7.4.0.0 2,7 ]trideca-1(9),2(7),3,5,10,12-hexaen-6-yl]-4-({2'-methanesulfinyl-5-[(9S)-9-methyl-2,5-dioxa-8-azaspiro[3,5]nonan-8-yl]-[3,4'-bipyridine]-6-yl}oxy)pyrrolidine-2-carboxylic acid [ka]

[0190] (2S,4S)-1-[4-(difluoromethyl)-8-oxa-3,5-diazatricyclo-[7.4.0.0 in 1.00 mL of DCM 2,7To a chilled solution of ]trideca-1(9),2(7),3,5,10,12-hexaen-6-yl]-4-({5-[(9S)-9-methyl-2,5-dioxa-8-azaspiro[3.5]nonanane-8-yl]-2'-(methylsulfanyl)-[3,4'-bipyridine]-6-yl}oxy)-pyrrolidine-2-carboxylic acid (e.g. 3.16, 25.0 mg, 0.04 mmol), meta-chloroperoxybenzoic acid (7.30 mg, 0.03 mmol) was added at -15°C. The reaction mixture was stirred at -15°C for 10 minutes and then purified by HPLC (Xbridge, ACN / H2O / TFA). ESI-MS:707 [M+H] + R t (HPLC): 0.85 min (Method H)

[0191] Example 6.01 (2S,4S)-4-({3-[(9S)-9-methyl-2,5-dioxa-8-azaspiro[3.5]nonan-8-yl]-5-(propa-1-in-1-yl)pyridine-2-yl}oxy)-1-[4-(trifluoromethyl)-8-oxa-3,5-diazatricyclo[7.4.0.0 2,7 ]Trideca-1(9),2(7),3,5,10,12-hexaen-6-yl]pyrrolidine-2-carboxylic acid [ka]

[0192] (2S,4S)-4-({5-bromo-3-[(9S)-9-methyl-2,5-dioxa-8-azaspiro[3.5]nonan-8-yl]pyridine-2-yl}oxy)-1-[4-(trifluoromethyl)-8-oxa-3,5-diazatricyclo[7.4.0.0 2,7To a degassed solution of trideca-1(9),2(7),3,5,10,12-hexaen-6-yl]pyrrolidine-2-carboxylic acid (e.g., 1.10, 150 mg, 0.230 mmol), copper(I) iodide (4.3 mg, 0.023 mmol) was added, followed by Pd(dppf)Cl2 (33 mg, 0.050 mmol). After stirring for several minutes, a 1 M solution of methylacetylene in THF (1.35 mL, 1.35 mmol) was added, and the mixture was heated at 75°C for 4 hours. The reaction mixture was diluted with ACN, acidified with acetic acid, filtered, and purified by HPLC (Xbridge, ACN / H2O / TFA). ESI-MS:624 [M+H] + R t (HPLC): 1.08 min (Method E)

[0193] The following example was prepared according to the general procedure described above (Example 6.01). [ka]

[0194] Example 7.01 (2S,4S)-4-({3-[(9S)-9-methyl-2,5-dioxa-8-azaspiro[3.5]nonan-8-yl]-5-(pyrimidine-5-yl)pyridine-2--yl}oxy)-1-[4-(trifluoromethyl)-8-oxa-3,5-diazatricyclo[7.4.0.0 2,7 ]Trideca-1(9),2(7),3,5,10,12-hexaen-6-yl]pyrrolidine-2-carboxylic acid [ka]

[0195] (2S,4S)-4-({3-[(9S)-9-methyl-2,5-dioxa-8-azaspiro[3.5]nonan-8-yl]-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine-2-yl}oxy)-1-[4-(trifluoromethyl)-8-oxa-3,5-diazatricyclo-[7.4.0.0 Xphos 3rd gen (15 mg, 0.018 mmol) was added to a degassed mixture of 2,7]-trideca-1(9),2(7),3,5,10,12-hexaen-6-yl]pyrrolidine-2-carboxylic acid (intermediate 16.1 mg, 220 mg, 0.309 mmol), potassium carbonate solution (2.0 mol / L, 0.463 mL, 0.928 mmol), and 4-bromo-1-cyclopropyl-1H-pyrazole (119 mg, 618 mmol). The reaction mixture was heated at 80°C for 2 hours, cooled to RT, and diluted with ethyl acetate. Saturated aqueous ammonium chloride solution and water were added. The phases were separated, and the aqueous layer was extracted with ethyl acetate. The mixed organic layers were washed with saturated ammonium chloride solution, dried over sodium sulfate, filtered, evaporated, and purified by HPLC (Sunfire, ACN / H2O / TFA). ESI-MS:692 [M+H] + R t (HPLC): 1.01 min (E)

[0196] The following example was prepared according to the general procedure described above (Example 7.01). [ka] [ka]

[0197] Example 8.01 (2S,4S)-4-{[5-(1-methyl-1H-1,2,3-triazol-4-yl)-3-[(9S)-9-methyl-2,5-dioxa-8-azaspiro[3.5]nonan-8-yl]pyridine-2-yl]oxy}-1-[4-(trifluoromethyl)-8-oxa-3,5-diazatricyclo[7.4.0.02,7 ]Trideca-1(9),2(7),3,5,10,12-hexaen-6-yl]pyrrolidine-2-carboxylic acid [ka]

[0198] A mixture of Example 1.12 (75 mg, 0.12 mmol), trimethylsilyl methyl azide (16 mg, 0.012 mmol), copper(II) sulfate (20 mg, 0.12 mmol), and sodium L-ascorbate (49 mg, 0.24 mmol) in a mixture of 1.00 mL of DMSO and 0.10 mL of water was stirred at RT for 1 hour. Next, 240 μL of 1 M TBAF solution was added and the reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was diluted with ACN / H2O, acidified with TFA, filtered, and purified by HPLC. ESI-MS:667 [M+H] + R t (HPLC): 0.87 min (Method P)

[0199] Example 9.01 (2S,4S)-1-[4-(difluoromethyl)-8-oxa-3,5-diazatricyclo[7.4.0.0 2,7 ]trideca-1(9),2(7),3,5,10,12-hexaen-6-yl]-4-({3-[(9S)-9-methyl-2,5-dioxa-8-azaspiro[3.5]nonan-8-yl]-5-(methylsulfanyl)pyridine-2-yl}oxy)pyrrolidine-2-carboxylic acid [ka]

[0200] (2S,4S)-4-({5-bromo-3-[(9S)-9-methyl-2,5-dioxa-8-azaspiro[3.5]nonane-8-yl]pyridine-2-yl}oxy)-1-[4-(difluoromethyl)-8-oxa-3,5-diazatricyclo[7.4.0.02,7]-trideca-1(9),2(7),3,5,10,12-hexaene-6 in 8.00 mL of dioxane A degassed mixture of -yl]pyrrolidine-2-carboxylic acid (intermediate 3.1.I(a), 160 mg, 0.25 mmol), XANTPHOS (20 mg, 0.035 mmol), sodium methanethiolate (0.25 mL, 0.59 mmol), DIPEA (0.100 mL, 0.58 mmol), and Pd2(dba)3 (16 mg, 0.017 mmol) was heated overnight at 110°C. After cooling to RT, ethyl acetate and water were added to the reaction mixture. The organic layer was separated, dried, concentrated under vacuum, and purified by HPLC (Sunfire C-18, H2O / ACN / TFA). ESI-MS:614 [M+H] + Rt (HPLC): 1.01 min (Method C)

[0201] Example 10.01 (2S,4S)-4-({3-[(9S)-9-methyl-2,5-dioxa-8-azaspiro[3.5]nonan-8-yl]-5-(1H-pyrazole-1-yl)pyridine-2-yl}oxy)-1-[4-(trifluoromethyl)-8-oxa-3,5-diazatricyclo[7.4.0.0 2,7 ]Trideca--1(9),2(7),3,5,10,12-hexaen-6-yl]pyrrolidine-2-carboxylic acid [ka]

[0202] (2S,4S)-4-({5-bromo-3-[(9S)-9-methyl-2,5-dioxa-8-azaspiro[3.5]nonan-8-yl]pyridine-2-yl}oxy)-1-[4-(trifluoromethyl)-8-oxa-3,5-diazatricyclo[7.4.0.0] in 1.50 mL of dioxane under an argon atmosphere. 2,7 tBuBrettPhos (5.00 mg, 0.006 mmol) was added to a degassed mixture of ]-trideca-1(9),2(7),3,5,10,12-hexaen-6-yl]pyrrolidine-2-carboxylic acid (Ex. 1.10, 30 mg, 0.045 mmol), LiHMDS (1 M in THF, 0.120 mL, 0.120 mmol), and pyrazole (5.00 mg, 0.073 mmol), and the mixture was heated at 80°C for 5 hours. After cooling to RT, the mixture was diluted with methanol, concentrated under vacuum, and purified by HPLC. ESI-MS:652 [M+H] + Rt (HPLC): 1.01 min (Method P)

[0203] Preparation of prodrugs: Prodrug P01 (2S,4S)-4-({3-[(9S)-9-methyl-2,5-dioxa-8-azaspiro[3.5]nonan-8-yl]pyridine-2-yl}oxy)-1-[4-(difluoromethyl)-8-oxa-3,5-diazatricyclo[7.4.0.0 2,7 ]Trideca-1(9),2(7),3,5,10,12-hexaen-6-yl]pyrrolidine-2-carboxylate methyl [ka]

[0204] (2S,4S)-4-({3-[(9S)-9-methyl-2,5-dioxa-8-azaspiro[3.5]nonan-8-yl]-pyridine-2-yl}-oxy)1-[4-(difluoromethyl)-8-oxa-3,5-diazatricyclo[7.4.0.0 2,7Trideca-1(13),2,4,6,9,11-hexaen-6-yl]pyrrolidine-2-carboxylic acid (e.g., 4.04 mg, 0.020 mmol) was mixed with O-methyl-N,N'-diisopropylurea (41 μL, 0.25 mmol). The reaction mixture was stirred at RT for 60 hours, then diluted with ACN / water and purified by HPLC (ACN / H2O / TFA). ESI-MS:582 [M+H] + R t (HPLC): 0.69 min (Method A)

[0205] The following compounds were prepared according to the general procedure described above (Prodrug P01). [ka]

[0206] List of abbreviations [Table 2-1] [Table 2-2]

[0207] Analytical HPLC method: [Table 3]

[0208] [Table 4]

[0209] [Table 5]

[0210] [Table 6]

[0211] Table 7

[0212] Table 8

[0213] Table 9

[0214] Table 10

[0215] Table 11

[0216] Table 12

[0217] Table 13

[0218] Table 14

[0219] Table 15

[0220] [Table 16]

[0221] [Table 17]

[0222] [Table 18] [Examples]

[0223] 5 examples 5.1 Compound examples The following compound examples of formula (I) or formula (I') summarized in Table 1 were synthesized, and their pharmacological properties regarding their efficacy in inhibiting cGAS activity were tested. In particular, "biochemical (in vitro) IC50 values" related to cGAS inhibition (hcGAS IC50), and "IC50 values ​​for inhibition of IFN induction in virus-stimulated THP1 cells" (THP (vir) IC50), "IC50 value for inhibition of IFN induction in cGAMP-stimulated THP1 cells" (THP (cGAMP) The IC50 and "IC50 values ​​for IFN-induced inhibition in dsDNA-stimulated human whole blood" (hWB IC50) were experimentally determined according to the assay method described in Section 6 below. The results are summarized in Table 1 below.

[0224] The compound examples of formula (I) or formula (I') summarized in Table 1 also exhibit the following properties. • Satisfactory "biochemical (in vitro) IC50 value for cGAS inhibition (≤100 nM, preferably ≤50 nM, especially hcGAS IC50 of ≤10 nM)" • Satisfactory "cellular IC50 value for cGAS inhibition" (≤1 μM, preferably ≤500 nM, more preferably ≤100 nM, especially ≤50 nM THP1 (vir) IC50) and • Satisfactory selectivity for cGAS inhibition (Ratio THP1 ≥ 10, more preferably ≥ 50, even more preferably ≥ 500, especially ≥ 1000) (cGAMP) IC50 / THP1 (vir) IC50). Furthermore, examples of compounds of formula (I) or formula (I') also show acceptable IC50 values ​​(hWB IC50) for inhibiting IFN induction in dsDNA-stimulated human whole blood.

[0225] Table 1: Pharmacological properties of examples of compounds of the present invention [Table 19-1] [Table 19-2] [Table 19-3] [Table 19-4] [Table 19-5] [Table 19-6] [Table 19-7] [Table 19-8] [Table 19-9] [Table 19-10] [Table 19-11] [Table 19-12] [Table 19-13] [Table 19-14] [Table 19-15] [Table 19-16] [Table 19-17] [Table 19-18] [Table 19-19]

[0226] 5.2 Comparison of compound examples and prior art compounds 5.2.1 Compounds of WO 2020 / 142729 WO 2020 / 142729 discloses cGAS inhibitors with partially similar structures. Pages 44 and 45 of WO 2020 / 142729 disclose the "biochemical (in vitro) IC50 value" (corresponding to "hcGAS IC50") for cGAS inhibition. As a result, compounds with a "biochemical (in vitro) IC50 value" of less than 100 nM were designated as "Group A," compounds with a "biochemical (in vitro) IC50 value" greater than 100 nM and less than 500 nM were designated as "Group B," compounds with a "biochemical (in vitro) IC50 value" greater than 500 nM and less than 1 μM were designated as "Group C," compounds with a "biochemical (in vitro) IC50 value" greater than 1 μM and less than 10 μM were designated as "Group D," and compounds with a "biochemical (in vitro) IC50 value" greater than 10 μM were designated as "Group E" (see page 44 of WO 2020 / 142729). Page 45 of WO 2020 / 142729 discloses that only compound number 25 could be designated as "Group A" due to having a "biochemical (in vitro) IC50 value" of less than 100 nM. All other compound examples in WO 2020 / 142729 show "biochemical (in vitro) IC50 values" greater than 100 nM.

[0227] 5.2.2 Comparison of the present invention with the example in WO 2020 / 142729 Selected prior art compounds from WO 2020 / 142729 were synthesized, and their pharmacological properties regarding their efficacy in inhibiting the cGAS / STING pathway were tested. In particular, for the structurally closest example to WO 2020 / 142729, the "biochemical (in vitro) IC50 value" for cGAS inhibition (hcGAS IC50) and the "cellular IC50 value for inhibition of IFN induction in virus-stimulated THP1 cells" (THP1) were tested according to the assay methods described in Section 6 below. (vir) IC50), "Cell IC50 values ​​for inhibition of IFN induction in cGAMP-stimulated THP1 cells" (THP1 (cGAMP)The IC50 and the "IC50 value for IFN-induced inhibition in human whole blood" (hWB) were experimentally determined (see Table 2 below).

[0228] Table 2: Pharmacological properties of selected compound examples from WO 2020 / 142729 [Table 20]

[0229] The pharmacological properties of the compound examples of the present invention summarized in Table 1 and the respective pharmacological properties of the compounds of WO 2020 / 142729 were experimentally determined according to the same assay procedure described in Section 6 below, and can therefore be compared with each other. From the data shown in Table 2, it is clear that all compound examples in WO 2020 / 142729, with the exception of example number 25 (designated as "Group A" in WO 2020 / 142729 with a "biochemical (in vitro) IC50 value" (=hcGAS IC50) of less than 100 nM), exhibit a "biochemical (in vitro) IC50 value" (=hcGAS IC50) significantly greater than 100 nM. This is in contrast to the fact that all compound examples of the present invention have a "biochemical (in vitro) IC50 value" (hcGAS IC50) of less than 100 nM. However, the compound of example number 25 in WO 2020 / 142729, which has a "biochemical (in vitro) IC50 value" (hcGAS IC50) of 55 nM, is related to THP1 for example number 25 in WO 2020 / 142729. (vir) Since IC50 is 17 μM, THP1 is less than 1 μM. (vir) It does not meet the selection criteria for "satisfactory cell inhibitory efficacy" as indicated by IC50.

[0230] 5.3 Prodrugs Esters of active drugs containing a carboxylic acid group are known to be viable prodrugs, meaning they can exhibit improved oral absorption / bioavailability compared to the individual active drug. Commonly used prodrugs of active drugs containing a carboxylic acid group include, for example, methyl esters, ethyl esters, and isopropyl esters (see Beaumont et al., Current Drug Metabolism, 2003, Vol. 4, Issue 6, 461-485). Furthermore, Nakamura et al., Bioorganic & Medicinal Chem., Vol. 15, Issue 24, p. 7720-7725 (2007) states that N-acylsulfonamide and N-acylsulfonylurea derivatives of specific active drugs having a free carboxylic acid group may also be viable prodrugs.

[0231] Furthermore, experimental clues revealed that methyl esters of compound examples of formula (I) or formula (I') are also viable prodrugs for cGAS inhibitors of formula (I) or formula (I'). Compounds P01, P02, P03, and P04 are methyl esters of compound examples 4.04, 1.10, 1.12, and 3.14, respectively, and can therefore be viable prodrugs of each of the respective compound examples. P01, P02, P03, and P04 were synthesized, and their pharmacological properties regarding their efficacy in inhibiting the cGAS / STING pathway were tested. Subsequently, the experimentally determined pharmacological properties of prodrugs P01, P02, P03, and P04 were compared with the corresponding pharmacological properties of compound examples 4.04, 1.10, 1.12, and 3.14, respectively, as summarized in Table 3 below. This comparison between a compound example and its corresponding prodrug indicates that the hcGAS IC50 value for the compound example is always around 10 nM or even lower, while the hcGAS IC50 value for the corresponding prodrug is always extremely high, generally greater than 9000 nM. This large difference between the compound example and its corresponding prodrug suggests that the respective THP1 values ​​between the compound example and its corresponding prodrug always remain within the same range. (vir) No IC50 values ​​were observed (see Table 3 for example number 4.04 and its respective prodrug P01).

[0232] One possible explanation for this finding is that all example compounds (which become "drugs") have a free carboxyl group, which appears to be crucial for inhibiting cGAS activity, while in all "prodrugs," the carboxyl group is masked by a carboxymethyl ester group. As a result, prodrugs lose their inhibitory efficacy in the "in vitro human cGAS enzyme assay" (see section 6.1 below) because there are no intracellular enzymes that cleave the carboxymethyl ester group in this assay. Therefore, prodrugs exhibit an extremely high "biochemical (in vitro) IC50 value" (=hcGAS IC50) in this "in vitro human cGAS enzyme assay," while the corresponding example compounds (which become drugs or active agents) exhibit a low "biochemical (in vitro) IC50 value" (=hcGAS IC50). In the "Human cGAS Cell Assay and Counter-Cell Assay" (see Section 6.2 below), an endogenous cellular enzyme exists that cleaves the carboxymethyl ester group. As a result, the compound example itself (meaning the drug or active agent itself) is small THP1 (vir) Not only does it show an IC50 value, but the corresponding prodrug is also relatively small: "THP1 (vir) This indicates the IC50 value. In this "human cGAS cell assay," the methyl ester of the prodrug is cleaved by endogenous intracellular enzymes to become the corresponding drug / active agent, which then exhibits inhibitory efficacy again. This explanation, along with the measurements shown in Table 3, means that while methyl ester derivatives of the compounds of formula (I) or formula (I') appear to be viable prodrugs of the compounds of formula (I) or formula (I'), they themselves do not exhibit inhibitory activity toward in vitro human biochemical cGAS inhibition. However, when the methyl ester is cleaved by endogenous intracellular enzymes, the compounds of formula (I) or formula (I') (activators) are formed, and they again exhibit inhibitory activity toward the cGAS / STING pathway.

[0233] Table 3: Examples of selected compounds (=active agents) of the present invention and a comparison of their respective methyl ester prodrugs: [Table 21-1] [Table 21-2]

[0234] 6. Biological Experiments The activity of the compound of the present invention can be demonstrated using the following in vitro cGAS enzyme assay and cell assay. 6.1 Method: Human cGAS enzyme assay (hcGAS IC50 (in vitro)) Human cGAS enzyme was activated in the presence of 45-base-pair double-stranded DNA, along with its substrates, GTP and ATP. The activity of the compound was determined by measuring its effect on the formation of cGAMP, the product of the enzymatic reaction, using mass spectrometry. Enzyme preparation: Human cGAS (amino acids 1-522) with an N-terminal 6x-His tag and a SUMO tag was expressed in E. coli BL21(DE3)pLysS(Novagen) cells at 18°C ​​for 16 hours. The cells were lysed in a buffer containing 25 mM Tris (pH 8), 300 mM NaCl, 10 mM imidazole, 10% glycerol, a protease inhibitor cocktail (cOmplete®, EDTA-free, Roche), and DNase (5 μg / mL). The cGAS protein was isolated by affinity chromatography on Ni-NTA agarose resin and purified by size exclusion chromatography using a Superdex 200 column (GE Healthcare) equilibrated with 20 mM Tris (pH 7.5), 500 mM KCl, and 1 mM TCEP. The purified protein was concentrated to 1.7 mg / mL and stored at -80°C.

[0235] Assay method The compounds were supplied to a 10 mM DMSO solution, serially diluted, and transferred to a 384-well assay plate (Greiner #781201) using an Echo acoustic dispenser. Typically, eight concentrations were used, achieved through approximately 1:5 dilution steps after the highest concentration of 10 μM in the final assay volume. The DMSO concentration was set to 1% in the final assay volume. The 384-well assay plate contained 22 test compounds (columns 1-22), with DMSO added to columns 23 and 24. After compound transfer, 15 μL of enzyme-DNA working solution (12 nM cGAS, 0.32 μM 45 base pair DNA, assay buffer, 10 mM Tris pH 7.5 / 10 mM KCl / 5 mM MgCl2 / 1 mM DTT) was added to each well of column 1-23 via a MultiDrop Combi dispenser. 15 μL of assay buffer without enzyme / DNA was added to column 24 as a low control. Next, the plates were pre-incubated at room temperature for 60 minutes. Subsequently, 10 μL of GTP (ThermoFisher #R0461)-ATP (Promega #V915B) mix in assay buffer was added to the assay plate using Multidrop Combi (columns 1-24, each with a final concentration of 30 μM). The plates were incubated again at room temperature for 90 minutes. After incubation, the reaction was stopped with 80 μL of 0.1% formic acid in an assay buffer containing 5 nM cyclic di-GMP (Sigma #SML1228), which was used as an internal standard for mass spectrometry. The total volume per well was 105 μL.

[0236] Rapidfire MS Detection The plate was centrifuged at 4000 rpm for 5 minutes at 4°C. A RapidFire autosampler was connected to a binary pump (Agilent 1290) and a Triple Quad 6500 (ABSciex, Toronto, Canada). The system consisted of a 10 μL loop, a 10 mM NH4Ac(aq) aqueous solution (pH 7.4) as eluent A (pump 1, 1.5 mL / min, pump 2, 1.25 mL / min), and a C18 [12 μL bed volume] cartridge (Agilent, part number G9210A) containing 10 mM NH4Ac in v / v / v 47.5 / 47.5 / 5 ACN / MeOH / H2O (pH 7.4) as eluent B (pump 3, 1.25 mL / min). Aspiration time: 250 ms; Loading time: 3000 ms; Elution time: 3000 ms; Washing volume: 500 μL. MS was operated in positive ion mode using a HESI ion source, a source temperature of 550°C, curtain gas = 35, gas 1 = 65, and gas 2 = 80. The unit mass resolution in SRM mode was determined. The following transitions and MS parameters (DP: declustering potential and CE: collision energy) were determined for cGAMP and DicGMP. Analytes: cGAMP, 675.1 / 524, DP=130, CE=30 and Internal standard: Cyclic GMP, 690.1 / 540, DP=130, CE=30. The formation of cGAMP was monitored and evaluated as a ratio to cyclic di-GMP. Data evaluation and calculation: For data evaluation and calculation, the low control measurements were set as the 0% control, and the high control measurements were set as the 100% control. The IC50 value was calculated using a standard four-parameter logistic regression equation. Calculation: [y=(ad) / (1+(x / c)^b)+d], a=low value, d=high value; x=conc M; c=IC50 M; b=slope

[0237] 6.2 Methods: Human cGAS cell assay and cGAMP-stimulated counter cell assay (THP1 (vir) IC50 and THP1 (cGAMP) IC50) As the basis for both assays, THP1-Dual® cells (InvivoGen #thpd-nfis) expressing an IRF-dependent Lucia luciferase reporter were used. To detect the cGAS activity of the cells, they were stimulated by infection with a baculovirus (pFastbac-1, Invitrogen, without coding insert) that provides a cGAS enzyme that stimulates double-stranded DNA (THP1 (vir) (Measurement of IC50) For the counterassay, cells were stimulated with cGAMP (SigmaAldrich #SML1232) to activate the same pathway immediately downstream of cGAS, independently of cGAS (THP1). (cGAMP) (Measurement of IC50) DNA-stimulated cGAS enzyme activity (THP1 (vir) Measurement of IC50) or direct cGAMP (THP1 (cGAMP) The activity of the pathway was monitored by measuring IC50 and Lucia luciferase activity induced by counterassays.

[0238] Assay method The compounds were supplied to a 10 mM DMSO solution, serially diluted, and transferred to a 384-well assay plate (Greiner #781201) using an Echo acoustic dispenser. Typically, eight concentrations were used, achieved through approximately 1:5 dilution steps after the highest concentration of 10 μM in the final assay volume. The DMSO concentration was set to 1% in the final assay volume. The 384-well assay plate contained 21 test compounds (columns 1-22), with DMSO added to columns 23 and 24. Cells cultured according to the manufacturer's conditions were harvested by centrifugation at 300g / 10min, then resuspended in fresh cell medium (RPMI 1640 (Gibco #A10491-01), 10% FCS (Gibco #10500), 1x GlutaMax (Gibco #35050-061), 1x Pen / Strep solution (Gibco #15140-122), 100μg / ml Normocin (InvivoGen #ant-nr), 100μg / ml Zeocin (InvivoGen #ant-zn), 10μg / ml Blasticidin S (Life Technologies #A11139-03)) and diluted to 1.66E5 cells / ml. Next, baculovirus solution was added to the cells at a ratio of 1:200 (adjusted according to the virus batch) (THP1 (vir) (Measurement of IC50). Alternatively, for a counterassay, cGAMP was added to cells at a final concentration of 10 μM (THP1). (cGAMP) (Measurement of IC50) 30 μL of cell / virus mix was added to each well of compound plates on columns 1-23 using a MultiDrop Combi dispenser (5000 cells / well). 30 μL / 5000 cells / well (virus-free) was added to column 24 as a low control. Next, the plates were incubated in a humidified incubator at 37°C for 18 hours. Subsequently, 15 μL of QuantiLuc detection reagent (InvivoGen #rep-qlcg5) was added to each well using MultiDrop Combi. Measurements were performed immediately after addition using an EnVision reader (US emission reading mode). Data evaluation and calculation: For data evaluation and calculation, the low control measurements were set as the 0% control, and the high control measurements were set as the 100% control. The IC50 value was calculated using a standard four-parameter logistic regression equation. Calculation: [y=(ad) / (1+(x / c)^b)+d], a=low value, d=high value; x=conc M; c=IC50 M; b=slope

[0239] 6.3 Method: Human whole blood assay (human WB IC50) To detect cellular cGAS activity, human whole blood was stimulated by transfection with double-stranded DNA. Pathway activity was monitored by measuring IFNα2α production. Assay method The compounds were supplied to a 10 mM DMSO solution, serially diluted, and transferred to a 96-well cell culture plate (Corning #3595) using an Echo acoustic dispenser. Each well was pre-filled with 20 μl of OptiMEM (Gibco, #11058-021). Typically, eight concentrations were used, achieved through approximately 1:5 dilution steps after the highest concentration of 10 μM in the final assay volume. The DMSO concentration was set to 1% in the final assay volume. The 96-well assay plate contained 10 test compounds, with DMSO added to the control wells. Human whole blood was collected concurrently from three or more healthy donors (female or male, free from medication for 7 days except contraceptives and thyroxine) as sodium citrate blood (e.g., 3.8% in Monovettes from Sarstedt). After collection, the whole blood was stored at room temperature for up to 3 hours before use in the assay. 160 μl of whole blood sample was transferred to each well of a 96-well assay plate filled with compound / OptiMEM. All assay plates were prepared twice using blood from different donors. The blood plates were kept at room temperature for 60 minutes with the lids on but not sealed, while being continuously shaken at 450 rpm. A DNA-Fugene mix (Herring DNA, Sigma Aldrich #D6898-1G, Fugene (5x1mL), Promega #E2312) was prepared in OptiMEM and incubated at RT for 10 minutes (125ng DNA / 20μl to Fugene ratio 9.6:1). 20μl of the DNA-Fugene mix was added to each well, resulting in a 125ng DNA / well / 200μl to Fugene ratio of 9.6:1. 20μl of OptiMEM and 9.6:1 Fugene were added to all low control wells. After covering the assay plate with a vent seal and lid, the blood plate was maintained at room temperature for 30 minutes with continuous shaking at 450 rpm, and then incubated overnight at 37°C for 22 hours without shaking.

[0240] To detect IFNα-2α in human plasma, biotin-labeled capture antibody (Antibody Set IFNA2, Meso Scale Diagnostics #B21VH-3, including coating and capture antibody) was diluted 1:17.5 with Diluent 100 (Meso Scale Diagnostics #R50AA-4) according to the manufacturer's instructions. A U-Plex MSD GOLD 96-well Small Spot Strepavidin SECTOR plate (Meso Scale Diagnostics # L45SA-5) was coated with 25 μl of diluted capture antibody. This coated plate was incubated at room temperature for 60 minutes with continuous shaking at 700 rpm. The MSD IFNα-2α plate was washed three times with 150 μl of washing buffer (1x HBSS, 0.05% Tween). The plates were blocked with 100 μl of block solution / well (1x HBSS and 0.2% Tween, 2% BSA) for 60 minutes while continuously shaking at 700 rpm at room temperature, and then removed immediately before continuing with human plasma to dry the plates as much as possible. The whole blood assay plates were centrifuged at 1600 rpm for 10 minutes. Using a pipetting robot, 25 μl of supernatant was transferred from each whole blood plate to the corresponding IFNα-2α plate. The plates were sealed with microplate seals and kept at room temperature for 2 hours with continuous shaking at 700 rpm. Next, the MSD IFNα-2α plate was washed three times with 150 μl of washing buffer (1x HBSS, 0.05% Tween), and then 25 μl of MSD SULFO-TAG IFNα-2α antibody solution (diluted 1:100 with Diluent 3 (Meso Scale Diagnostics # R50AP-2)) was added to the plate wells. The plate was then sealed with a microplate seal and kept at room temperature for 2 hours with continuous shaking at 700 rpm. Finally, the MSD IFNα-2α plate was washed three times with 150 μl of washing buffer (1x HBSS, 0.05% Tween). 150 μl of 2x Read buffer was added to each well, and the plate was immediately measured using a vendor barcode with an MSD Sector S600 reader. Data evaluation and calculation: For data evaluation and calculation, the percentage control calculation for each well was based on the mean of high control (DNA-stimulated control) and low control (unstimulated control) using the following formula. [Count (Sample) - Count (Low)) / (Count (High) - Count (Low))] * 100 The IC50 value was calculated using a standard four-parameter logistic regression equation. Calculation: [y=(ad) / (1+(x / c)^b)+d], a=low value, d=high value; x=conc M; c=IC50 M; b=slope

[0241] 7. Indications As has become clear, the compounds of formula (I) or formula (I') are characterized by their range of applications in the therapeutic field. In particular, the applications in which the compounds of formula (I) or formula (I') of the present invention are preferably used as cGAS inhibitors based on their pharmaceutically active properties should be mentioned. The cGAS pathway is important for host defense against pathogen invasion, such as viral infections and invasions by some intracellular bacteria, but cellular stress and genetic factors, such as nuclear or mitochondrial leakage, can also lead to the production of abnormal cellular dsDNA, thereby triggering an autoinflammatory response. As a result, cGAS inhibitors have potent therapeutic potential for use in the treatment of a variety of autoinflammatory and autoimmune diseases. An et al., Arthritis Rheumatol. 2017 Apr;69(4):800-807, disclosed that cGAS expression in peripheral blood mononuclear cells (PBMCs) is significantly higher in patients with systemic lupus erythematosus (SLE), a more autoimmune disease, compared to normal controls. Targeted measurement of cGAMP by tandem mass spectrometry detected cGAMP in 15% of the SLE patients tested, but not in normal or rheumatoid arthritis controls. SLE patients with cGAMP had higher disease activity compared to patients without cGAMP. While higher cGAS expression may result from exposure to type I interferon (IFN), the detection of cGAMP in SLE patients with high disease activity suggests the possibility of improvement in the cGAS pathway in disease manifestation.

[0242] Park et al., Ann Rheum Dis. 2018 Oct;77(10):1507-1515 also disclose improvements in the cGAS pathway in the development of SLE. Thim-Uam et al., iScience 2020 Sep 4;23(9), 101530 (doi: 10.1016 / j.isci.2020.101530) disclose that the STING pathway mediates lupus by activating conventional dendritic cell maturation and plasmacytoid dendritic cell differentiation. Gao et al., Proc. Natl. Acad. Sci. US A. 2015 Oct 20;112(42):E5699-705, state that activation of cGAS by autologous DNA is a cause of certain autoimmune diseases, such as interferonopathy. Tonduti et al., Expert Rev. Clin. Immunol. 2020 Feb;16(2):189-198, disclose that cGAS inhibitors have certain therapeutic potential for Eicardi-Gutierre syndrome, a severe autoinflammatory immune-mediated disorder similar to lupus. Yu et al., Cell 2020 Oct 29;183(3):636-649 describes the association between TDP-43-induced mitochondrial DNA and cGAS / STING pathway activation in amyotrophic lateral sclerosis (ALS). Ryu et al., Arthritis Rheumatol. 2020 Nov;72(11):1905-1915 also showed that bioactive plasma mitochondrial DNA is associated with disease progression in specific fibrous diseases, such as systemic sclerosis (SSc) or interstitial lung diseases (ILDs), progressive fibrous interstitial lung disease (PF-ILDs), and idiopathic pulmonary fibrosis (IPF). Schuliga et al., Clin. Sci. (Lond). 2020 Apr 17;134(7):889-905 describes how autologous DNA perpetuates senescence in IPF lung fibroblasts in a cGAS-dependent manner.

[0243] Further scientific clues linking the cGAS / STING pathway to the causes of other fibrotic diseases, such as non-alcoholic steatohepatitis (NASH), are described in Yu et al., J. Clin. Invest. 2019 Feb 1;129(2):546-555, and Cho et al., Hepatology. 2018 Oct;68(4): 1331-1346. Nascimento et al., Sci. Rep. 2019 Oct 16;9(1):14848 disclosed that auto-DNA release and STING-dependent sensing in mice lead to tobacco smoke-induced inflammation, suggesting a link between the cGAS-STING pathway and chronic obstructive pulmonary disease (COPD). Ma et al., Sci. Adv. 2020 May 20;6(21):eaaz6717 disclosed that ulcerative colitis and inflammatory bowel disease (IBD) can be suppressed by controlling cGAS-mediated inflammation. Gratia et al., J. Exp. Med. 2019 May 6;216(5):1199-1213, showed that Bloom syndrome proteins suppress innate immune sensing of micronuclei by cGAS. Consequently, cGAS inhibitors have therapeutic potential in the treatment of Bloom syndrome. Kerur et al., Nat. Med. 2018 Jan;24(1):50-61, report that cGAS plays an important role in non-standard inflammasome activation in age-related macular degeneration (AMD).

[0244] Furthermore, cGAS inhibitors of formula (I) or formula (I') also have therapeutic potential in the treatment of cancer (see Hoong et al., Oncotarget. 2020 Jul 28;11(30):2930-2955, and Chen et al., Sci. Adv. 2020 Oct 14;6(42):eabb8941). Furthermore, cGAS inhibitors of formula (I) or formula (I') also have therapeutic potential in the treatment of heart failure (Hu et al., Am. J. Physiol. Heart Circ. Physiol. 2020 Jun 1;318(6):H1525-H1537). Further scientific clues exist regarding the correlation between Parkinson's disease and the cGAS / STING pathway (Sliter et al., Nature. 2018 Sep;561(7722):258-262) and the correlation between Sjögren's syndrome and the cGAS / STING pathway (Papinska et al., J. Dent. Res. 2018 Jul;97(8):893-900). Furthermore, cGAS inhibitors of formula (I) or formula (I') also have therapeutic potential in the treatment of COVID-19 / SARS-CoV-2 infection, as shown in Di Domizio et al., Nature. 2022 Jan 19. doi: 10.1038 / s41586-022-04421-w: "The cGAS-STING pathway drives type I IFN immunopathology in COVID-19", and Neufeldt et al., Commun Biol. 2022 Jan 12;5(1):45. doi: 10.1038 / s42003-021-02983-5: "SARS-CoV-2 infection induces a pro-inflammatory cytokine response through cGAS-STING and NF-kappaB". Furthermore, cGAS inhibitors of formula (I) or formula (I') have therapeutic potential in the treatment of renal inflammation and renal fibrosis, as shown in Chung et al., Cell Metab. 2019 30:784-799: "Mitochondrial Damage and Activation of the STING Pathway Lead to Renal Inflammation and Fibrosis" and Maekawa et al., Cell Rep. 2019 29:1261-1273: "Mitochondrial Damage Causes Inflammation via cGAS-STING Signaling in Acute Kidney Injury".

[0245] Furthermore, cGAS inhibitors of formula (I) or formula (I') have therapeutic potential in the treatment of cancer, as shown in Bakhoum et al., Nature. 2018 Jan 25;553(7689):467-472: "Chromosomal instability drives metastasis through a cytosolic DNA response" and Liu et al., Nature. 2018 Nov;563(7729):131-136: "Nuclear cGAS suppresses DNA repair and promotes tumorigenesis". Furthermore, cGAS inhibitors of formula (I) or formula (I') have therapeutic potential in the treatment of metabolic disorders. This is because STING gt Animals showed decreased macrophage infiltration in adipose tissue under subchronic high-calorie intake (HFD) conditions, and STING gt Furthermore, IRF3 deficiency leads to decreased blood glucose and insulin levels, as well as weight loss (Mao et al, Arterioscler Thromb Vasc Biol, 2017;37 (5): 920-929). Furthermore, cGAS inhibitors of formula (I) or formula (I') have therapeutic potential in the treatment of vascular diseases, leading to vascular repair / regeneration. This is because the release of mitochondrial DNA into the cytosol of endothelial cells results in activation of the cGAS / STING pathway and suppression of endothelial proliferation. In addition, knockout of the cGAS gene restores endothelial repair / regeneration in a mouse model of inflammatory lung injury (Huang et al, Immunity, 2020, Mar 2017; 52 (3): 475-486.e5. doi: 10.1016 / j.immuni.2020,02.002). Furthermore, cGAS inhibitors of formula (I) or formula (I') have therapeutic potential in the treatment of age-related and obesity-associated cardiovascular diseases (Hamann et al, Immun Ageing, 2020, Mar 14; 17: 7; doi: 10.1186 / s12979-020-00176-y.eCollection 2020).

[0246] As a result, compounds of formula (I) or formula (I') as cGAS inhibitors can be used to treat autoinflammatory and autoimmune diseases, such as systemic lupus erythematosus (SLE), interferonopathy, Eicardi-Gutierre syndrome, age-related macular degeneration (AMD), amyotrophic lateral sclerosis (ALS), inflammatory bowel disease (IBD), chronic obstructive pulmonary disease (COPD), Bloom syndrome, Sjögren's syndrome, and Parkinson's disease. Furthermore, compounds of formula (I) or formula (I') as cGAS inhibitors can be used to treat fibrous diseases, such as systemic sclerosis (SSc), interferonopathy, non-alcoholic steatohepatitis (NASH), interstitial lung disease (ILD), preferably progressive fibrous interstitial lung disease (PF-ILD), and especially idiopathic pulmonary fibrosis (IPF). Furthermore, compounds of formula (I) or formula (I') as cGAS inhibitors can be used to treat age-related macular degeneration (AMD), heart failure, COVID-19 / SARS-CoV-2 infection, nephritis, renal fibrosis, metabolic disorders, vascular diseases, cardiovascular diseases, and cancer.

[0247] 8 combinations Compounds of formula (I) or formula (I') may be administered to patients alone or in combination with one or more other pharmacologically active agents. In preferred embodiments of the present invention, the compound of formula (I) or formula (I') may be used in combination with one or more pharmacologically active agents selected from the group consisting of anti-inflammatory agents, antifibrotic agents, antiallergic / antihistamines, bronchodilators, β2 agonists / beta-mimetics, adrenergic agonists, anticholinergics, methotrexate, mycophenolate mofetil, leukotriene modifiers, JAK inhibitors, anti-interleukin antibodies, nonspecific immunotherapeutic agents, such as interferon or other cytokines / chemokines, cytokine / chemokine receptor modifiers (i.e., cytokine receptor agonists or antagonists), Toll-like receptor agonists (=TLR agonists), immune checkpoint modulators, anti-TNF antibodies, such as adalimumab (Humira®), and anti-BAFF agents (Belimumab and Etanercept).

[0248] The antifibrotic agent is preferably selected from pirfenidone and tyrosine kinase inhibitors, such as nintedanib, with nintedanib being particularly preferred. Preferred examples of anti-inflammatory drugs are NSAIDs and corticosteroids. The NSAID is preferably selected from ibuprofen, naproxen, diclofenac, meloxicam, celecoxib, acetylsalicylic acid (Aspirin®), indomethacin, mefenamic acid, and etoricoxib. The corticosteroid is preferably selected from flunisolide, beclomethasone, triamcinolone, budesonide, fluticasone, mometasone, ciclesonide, rofleponide, and dexametasone. The antiallergic / antihistamine is preferably selected from epinastine, cetirizine, azelastine, fexofenadine, levocabastine, loratadine, ebastine, desloratidine, and mizolastine.

[0249] The β2 agonist / beta-mimetic may be a long-acting β2 agonist (LABA) or a short-acting β2 agonist (SABA). Particularly preferred β2 agonists / mimetics are selected from bambuterol, bitolterol, carbuterol, clenbuterol, fenoterol, formoterol, hexoprenalin, ibuterol, pirbuterol, procaterol, reproterol, salmeterol, sulfonterol, terbutalin, tolubuterol, olodaterol, and salbutamol, especially olodaterol. The anticholinergic agent is preferably selected from ipratropium salt, tiotropium salt, glycopyrronium salt, and theophylline, with tiotropium bromide being particularly preferred. The leukotriene modifier is preferably selected from montelukast, pranlukast, zafirlukast, ibudilast, and zileuton. JAK inhibitors are preferably selected from baricitinib, cerdulatinib, fedratinib, filgotinib, gandotinib, restaurtinib, momerotinib, pacritinib, peficitinib, ruxolitinib, tofacitinib, and upadacitinib. The anti-interleukin antibody is preferably selected from anti-IL23 antibodies, such as risankizumab, anti-IL17 antibodies, anti-IL1 antibodies, anti-IL4 antibodies, anti-IL13 antibodies, anti-IL-5 antibodies, anti-IL-6 antibodies, such as tocilizumab (Actemra®), anti-IL-12 antibodies, and anti-IL-15 antibodies.

[0250] 9. Formulations The compounds of the present invention may be administered by any appropriate route of administration, including systemic and topical administration. Systemic administration includes oral, parenteral, transdermal, rectal, and inhalation administration. Parenteral administration refers to routes of administration other than enteral, transdermal, or inhalation administration, and is typically by injection or infusion. Parenteral administration includes intravenous, intramuscular, intrasternal, and subcutaneous injection or infusion. Inhalation refers to administration into the patient's lungs, whether by inhalation through the mouth or nasal cavity. Topical administration includes application to the skin. The compounds of the present invention may also be administered by eye drops to treat Sjögren's syndrome. Suitable forms for administration include, for example, tablets, capsules, liquids, syrups, emulsions, or inhalable powders or sprays. In all cases, the content of the pharmaceutically effective compound must be within the range of 0.1 to 90 wt.%, preferably 0.5 to 50 wt.%, of the total composition, i.e., within a range sufficient to achieve the drug dose range described later. The preparation may be administered orally in tablet form, as a powder, as a powder in capsules (e.g., hard gelatin capsules), or as a solution or suspension. When administered by inhalation, the combination of active substances may be administered as a powder, as an aqueous solution or ethanol aqueous solution, or using a spray gas preparation.

[0251] Therefore, preferably, the pharmaceutical formulation is characterized by the content of one or more compounds of formula (I) or formula (I') according to the preferred embodiment described above. It is particularly preferable to administer the compound of formula (I) or formula (I') orally, and it is also particularly preferable to administer the compound of formula (I) or formula (I') once or twice daily. Suitable tablets can be obtained, for example, by mixing the active substance with known excipients, such as inert diluents, such as calcium carbonate, calcium phosphate, or lactose; disintegrants, such as corn starch or alginic acid; binders, such as starch or gelatin; lubricants, such as magnesium stearate or talc; and / or delayed-release agents, such as carboxymethylcellulose, cellulose acetate, or polyvinyl acetate. The tablets may contain several layers. Therefore, coated tablets can be prepared by coating a core, prepared in the same manner as a tablet, with a substance commonly used for tablet coating, such as coridone or shellac, gum arabic, talc, titanium dioxide, or sugar. The core may consist of several layers to achieve delayed release or to prevent incompatibility. Similarly, a tablet coating consisting of several layers can achieve delayed release, possibly using the excipients described above for tablets. The syrup containing the active substance of the present invention or a combination thereof may further contain a sweetener, such as saccharin, cyclamate, glycerol, or sugar, and a flavor enhancer, such as a fragrance, such as vanillin or orange extract. They may also contain a suspension adjuvant or thickener, such as sodium carboxymethylcellulose, a wetting agent, such as a condensation product of fatty alcohol and ethylene oxide, or a preservative, such as p-hydroxybenzoate.

[0252] Capsules containing one or more active substances or combinations of active substances can be prepared, for example, by mixing the active substances with an inert carrier, such as lactose or sorbitol, and filling them into gelatin capsules. Suitable suppositories can be prepared, for example, by mixing them with a carrier provided for this purpose, such as a neutral fat or polyethylene glycol or a derivative thereof. Examples of excipients that can be used include water, pharmaceutically acceptable organic solvents such as paraffin (e.g., petroleum fractions), vegetable oils (e.g., peanut oil or sesame oil), monofunctional or polyfunctional alcohols (e.g., ethanol or glycerol), carriers such as natural mineral powders (e.g., kaolin, clay, talc, chalk), synthetic mineral powders (e.g., highly dispersible silicic acid and silicates), sugars (e.g., sucrose, lactose, and glucose), emulsifiers (e.g., lignin, spent sulfite liquor, methylcellulose, starch, and polyvinylpyrrolidone), and lubricants (e.g., magnesium stearate, talc, stearic acid, and sodium lauryl sulfate). For oral administration, tablets may, of course, contain additives such as sodium citrate, calcium carbonate, and dicalcium phosphate, in addition to the carrier mentioned above, together with various other additives such as starch, preferably potato starch, gelatin, etc. Furthermore, lubricants such as magnesium stearate, sodium lauryl sulfate, and talc may be used simultaneously for the tableting process, and in the case of an aqueous suspension, the active substance may be added to the above excipients and used in combination with various flavor enhancers or colorants. Another aspect of the present invention may be as follows: [1] The following formula (I) [ka] (In the formula, R 1 It is selected from methyl, ethyl, halomethyl, haloethyl and halogen, G is O, NR 8 CH 2 , C and CR 8R 9 Selected from, R 2 H, halogen, cyclopropyl, C 1-3 -alkyl, -C 2-5 Selected from -alkynyl, -S-methyl and CN, or R 2 R is a cyclic group, which is selected from the group consisting of 5- to 6-membered heteroaryls containing 1, 2, 3, or 4 heteroatoms independently selected from phenyl or N, S, and O, and this cyclic group has one or two identical or different substituents R 10 Replaced by, R 3 is H or methyl, R 4 is H or methyl, R 5 These are H, methyl, -CN, -methylene-OH and -CF 3 Selected from, or R 5 It does not need to exist, R 6 These are H, methyl, -CN, -methylene-OH and -CF 3 Selected from, or R 5 and R 6 Together with the intermediate C atom, it forms a ring selected from oxetane, tetrahydrofuran, and cyclopropane. R 7 H, halogen, (C 1-3 )-alkyl and halo-(C 1-3 )-Selected from alkyl groups, R 8 It is selected from CN, H and methyl, R 9 It is selected from H, methyl and halogen, or R 9 It does not need to exist, Here, each R 10 These are hydrogen, halogen, haloalkyl, -methyl, -ethyl, -NH-CO-methyl, -N(CH 3 ) 2 , -CH 2 -OH, -NH(CH 3 ), -O-(C 1-3 -alkyl), -CN, -S-CH 3 ,-CO-NH 2 , -CH 2 -NH(CH 3 ), -CH 2 -NH 2 , -SO-(CH 3 ), cyclopropyl and -OR 11 Independently selected from the group consisting of, R 11 This is a 5-membered or 6-membered heteroring having one or two heteroatoms independently selected from N, O, and S. Or G is CR 8 R 9 And R 5 and R 9 It does not exist, and R 8 and R 6 and R 8 and R 6 The two intermediate carbon atoms form a condensed five-membered aromatic or non-aromatic heteroring containing one, two, or three heteroatoms independently selected from N, S, and O, respectively. Or G is CR 8 R 9 And R 8 and R 9 However, R 8 and R 9 (It forms a diazirine ring together with the intermediate C atom.) compounds and its prodrugs or pharmaceutically acceptable salts. [2] The following formula (I')

change

[14] above, and its prodrugs or pharmaceutically acceptable salts.

[16] G is O, R 3 or R 4 One of them is methyl, and the other is H. The compounds described in

[15] above, and its prodrugs or pharmaceutically acceptable salts. 〔17〕R 4 is methyl, R 3 H is, R 5 and R 6 However, it forms an oxetane ring together with the intermediate C atom. The compound described in

[16] above, and its prodrugs or pharmaceutically acceptable salts.

[18] G is CR 8 R 9 And, R8 and R 6 And, R 8 and R 6 The two intermediate C atoms form a condensed 5-membered aromatic heteroring containing one or two heteroatoms independently selected from N and O, respectively, and this ring is selected from a condensed isoxazolyl ring, a condensed pyrazolyl ring, a condensed pyrrolyl ring and a condensed furanyl ring. R 9 and R 5 It does not exist. A compound of formula (I) described in [1] above or a compound of formula (I') described in [2] above, and its prodrugs or pharmaceutically acceptable salts.

[19] See below

change

change

change

change

change

change

change

[20] The following formula (IV)

change

change

change

change

[21] The following formula (A)

change

change

[19] . 〔22〕R 12 A prodrug of formula (A) or formula (A') as described in

[21] above, wherein is methyl.

[23] A compound of formula (I) or formula (I') described in any one of items [1] to

[19] above, for use in treating diseases that can be treated by inhibition of cGAS.

[24] A compound of formula (I) or formula (I') described in any one of the above items [1] to

[19] for use in the treatment of diseases selected from the group consisting of systemic lupus erythematosus (SLE), interferonopathy, Eicardi-Gutierre syndrome, age-related macular degeneration (AMD), amyotrophic lateral sclerosis (ALS), inflammatory bowel disease (IBD), chronic obstructive pulmonary disease (COPD), Bloom syndrome, Sjögren's syndrome, Parkinson's disease, heart failure and cancer, systemic sclerosis (SSc), non-alcoholic steatohepatitis (NASH), interstitial lung disease (ILD), preferably progressive fibrous interstitial lung disease (PF-ILD), and especially idiopathic pulmonary fibrosis (IPF).

[25] A compound of formula (I) or formula (I') described in any one of the above items [1] to

[19] for use in the treatment of a disease selected from the group consisting of systemic lupus erythematosus (SLE), interferonopathy, Eicardi-Gutierre syndrome, age-related macular degeneration (AMD), amyotrophic lateral sclerosis (ALS), inflammatory bowel disease (IBD), chronic obstructive pulmonary disease (COPD), Bloom syndrome, Sjögren's syndrome, and Parkinson's disease.

[26] A compound of formula (I) or formula (I') described in any one of the above items [1] to

[19] for use in the treatment of a disease selected from the group consisting of systemic sclerosis (SSc), non-alcoholic steatohepatitis (NASH), interferonopathy, interstitial lung disease (ILD), preferably progressive fibrous interstitial lung disease (PF-ILD), and especially idiopathic pulmonary fibrosis (IPF).

[27] A compound of formula (I) or formula (I') described in any one of the above items [1] to

[19] for use in the treatment of a disease selected from the group consisting of age-related macular degeneration (AMD), heart failure, COVID-19 / SARS-CoV-2 infection, nephritis, nephropathy, metabolic disorders, vascular diseases, cardiovascular diseases, and cancer.

[28] A pharmaceutical composition comprising a compound of formula (I) or formula (I') as described in any one of items [1] to

[19] above, and optionally comprising one or more pharmaceutically acceptable carriers and / or excipients.

[29] A pharmaceutical composition comprising a compound of formula (I) or formula (I') described in any one of the above items [1] to

[19] , in combination with one or more active agents selected from the group consisting of anti-inflammatory agents, antifibrotic agents, antiallergic agents / antihistamines, bronchodilators, β2 agonists / beta-mimetics, adrenergic agents, anticholinergic agents, methotrexate, mycophenolate mofetil, leukotriene modifiers, JAK inhibitors, anti-interleukin antibodies, nonspecific immunotherapy agents, such as interferon or other cytokines / chemokines, cytokine / chemokine receptor modifiers, Toll-like receptor agonists, immune checkpoint modulators, anti-TNF antibodies, such as adalimumab, anti-BAFF antibodies, such as belimumab and etanercept.

[30] The pharmaceutical composition according to

[29] , wherein a compound of formula (I) or formula (I') is combined with one or more antifibrotic agents selected from the group consisting of pirfenidone and nintedanib.

[31] The pharmaceutical composition according to

[29] , wherein a compound of formula (I) or formula (I') is combined with one or more anti-inflammatory agents selected from the group consisting of NSAIDs and corticosteroids.

[32] The pharmaceutical composition according to

[29] , wherein a compound of formula (I) or formula (I') is combined with one or more active agents selected from the group consisting of bronchodilators, β2 agonists / beta-mimetics, adrenergic agonists and anticholinergics.

[33] The pharmaceutical composition according to

[29] , wherein a compound of formula (I) or formula (I') is combined with one or more anti-interleukin antibodies selected from the group consisting of an anti-IL-23 antibody, such as risankizumab; an anti-IL-17 antibody; an anti-IL-1 antibody; an anti-IL-4 antibody; an anti-IL-13 antibody; an anti-IL-5 antibody; an anti-IL-6 antibody, such as tocilizumab; an anti-IL-12 antibody; and an anti-IL-15 antibody.

Claims

1. The following formula (I) 【Chemistry 1】 (In the formula, R 1 It is selected from methyl, ethyl, halomethyl, haloethyl and halogen, G is O, NR 8 CH 2 , C and CR 8 R 9 Selected from, R 2 R is a cyclic group, which is selected from the group consisting of 5- to 6-membered heteroaryls containing phenyl and 1, 2, 3, or 4 heteroatoms independently selected from N, S, and O, and this cyclic group has one or two identical or different substituents R 10 Replaced by, R 3 is H or methyl, R 4 is H or methyl, R 5 These are H, methyl, -CN, -methylene-OH and -CF 3 Selected from, or R 5 It does not need to exist, R 6 These are H, methyl, -CN, -methylene-OH and -CF 3 Selected from, or R 5 and R 6 Together with the intermediate C atom, it forms a ring selected from oxetane, tetrahydrofuran, and cyclopropane. R 7 H, halogen, (C 1-3 )-alkyl and halo-(C 1-3 )-Selected from alkyl groups, R 8 It is selected from CN, H and methyl, R 9 It is selected from H, methyl and halogen, or R 9 It does not need to exist, Here, each R 10 These are hydrogen, halogen, haloalkyl, -methyl, -ethyl, -NH-CO-methyl, -N(CH 3 ) 2 ,-CH 2 -OH, -NH(CH 3 ), -O-(C 1-3 -alkyl), -CN, -S-CH 3 ,-CO-NH 2 ,-CH 2 -NH(CH 3 ), -CH 2 -NH 2 , -SO-(CH 3 ), cyclopropyl and -OR 11 Independently selected from the group consisting of, R 11 This is a 5-membered or 6-membered heteroring having one or two heteroatoms independently selected from N, O, and S. Or G is CR 8 R 9 And R 5 and R 9 It does not exist, and R 8 and R 6 and R 8 and R 6 The two intermediate carbon atoms form a condensed five-membered aromatic or non-aromatic heteroring containing one, two, or three heteroatoms independently selected from N, S, and O, respectively. Or G is CR 8 R 9 And R 8 and R 9 However, R 8 and R 9 (It forms a diazirine ring together with the intermediate C atom.) compounds or its pharmaceutically acceptable salts or stereoisomers.

2. The following formula (I') 【Chemistry 2】 (In the formula, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 (and G is as described in claim 1) The compound according to claim 1, or its pharmaceutically acceptable salts or stereoisomers.

3. R 7 However, selected from H, F, Cl, methyl, ethyl, halomethyl and haloethyl, A compound of formula (I) as described in claim 1 or a compound of formula (I') as described in claim 2, or its pharmaceutically acceptable salts or stereoisomers.

4. R 1 However, selected from halomethyl, haloethyl and methyl, A compound of formula (I) as described in claim 1 or a compound of formula (I') as described in claim 2, or its pharmaceutically acceptable salts or stereoisomers.

5. R 1 However, -CF 3 , -CHF 2 and -CH 2 A fluoromethyl selected from the group consisting of F. The compound according to claim 3, or its pharmaceutically acceptable salts or stereoisomers.

6. R 3 and R 4 At least one of them is methyl, A compound of formula (I) as described in claim 1 or a compound of formula (I') as described in claim 2, or its pharmaceutically acceptable salts or stereoisomers.

7. R 3 and R 4 One of them is methyl, and the other is H. A compound of formula (I) as described in claim 1 or a compound of formula (I') as described in claim 2, or its pharmaceutically acceptable salts or stereoisomers.

8. G is O, A compound of formula (I) as described in claim 1 or a compound of formula (I') as described in claim 2, or its pharmaceutically acceptable salts or stereoisomers.

9. G is O, and R 3 or R 4 One of them is methyl, and the other is H. A compound of formula (I) as described in claim 1 or a compound of formula (I') as described in claim 2, or its pharmaceutically acceptable salts or stereoisomers.

10. R 4 is methyl, and R 3 H is, R 5 and R 6 However, it forms an oxetane ring together with the intermediate C atom. The compound according to claim 8, or its pharmaceutically acceptable salts or stereoisomers.

11. R 2 R is a cyclic group, which is selected from the group consisting of 5- to 6-membered heteroaryls containing phenyl and 1, 2, or 3 heteroatoms selected from N, S, and O, and this cyclic group has one or two identical or different substituents R 10 Replaced by, Each R 10 is independently selected from the group consisting of hydrogen, halogen, haloalkyl, -methyl, -ethyl, -NH-CO-methyl, -N(CH 3 ) 2 , -CH 2 -OH, -NH(CH 3 ), -O-CH 3 , -CN, -S-CH 3 , -CO-NH 2 , -CH 2 -NH(CH 3 ), -CH 2 -NH 2 , -SO-(CH 3 ), cyclopropyl and -O-R 11 ; Each R 11 This is selected from a 5-membered to 6-membered heteroring containing one or two heteroatoms independently selected from N and O. A compound of formula (I) as described in claim 1 or a compound of formula (I') as described in claim 2, or its pharmaceutically acceptable salts or stereoisomers.

12. R 2 However, it is a cyclic group selected from the group consisting of pyrazolyl, pyridinyl, imidazolyl, phenyl, and isoxazolyl. This cyclic group is substituted with one or two identical or different substituents R 10 and Each R 10 These are hydrogen, halogen, haloalkyl, -methyl, -ethyl, -NH-CO-methyl, -N(CH 3 ) 2 ,-CH 2 -OH, -NH(CH 3 ), -O-CH 3 -CN, -S-CH 3 ,-CO-NH 2 ,-CH 2 -NH(CH 3 ), -CH 2 -NH 2 , -SO-(CH 3 ), cyclopropyl and -OR 11 Independently selected from the group consisting of, Each R 11 It is tetrahydropyran, The compound according to claim 11, or its pharmaceutically acceptable salts or stereoisomers.

13. G is O, R 3 or R 4 One of them is methyl, and the other is H. The compound according to claim 12, or its pharmaceutically acceptable salts or stereoisomers.

14. R 4 is methyl, and R 3 H is, R 5 and R 6 However, it forms an oxetane ring together with the intermediate C atom. The compound according to claim 13, or its pharmaceutically acceptable salts or stereoisomers.

15. G is CR 8 R 9 And, R 8 and R 6 And, R 8 and R 6 The two intermediate carbon atoms form a condensed five-membered aromatic heteroring containing one or two heteroatoms independently selected from N and O, and this ring is selected from a condensed isoxazolyl ring, a condensed pyrazolyl ring, a condensed pyrrolyl ring, and a condensed furanyl ring. R 9 and R 5 It does not exist. A compound of formula (I) as described in claim 1 or a compound of formula (I') as described in claim 2, or its pharmaceutically acceptable salts or stereoisomers.

16. The following compounds: 【Transformation 3】 【change】 【change】 【change】 Selected from the group consisting of, The compound of formula (I) described in claim 1, or its pharmaceutically acceptable salts or stereoisomers.

17. The compound of formula (I) described in claim 1, or a pharmaceutically acceptable salt or stereoisomer thereof.

18. The compound of formula (I) described in claim 1, or a pharmaceutically acceptable salt or stereoisomer thereof.

19. The compound of formula (I) described in claim 1, or a pharmaceutically acceptable salt or stereoisomer thereof.

20. The compound of formula (I) described in claim 1, or a pharmaceutically acceptable salt or stereoisomer thereof.

21. The compound of formula (I) described in claim 1, or a pharmaceutically acceptable salt or stereoisomer thereof.

22. The compound of formula (I) described in claim 1, or a pharmaceutically acceptable salt or stereoisomer thereof.

23. The compound of formula (I) described in claim 1, or a pharmaceutically acceptable salt or stereoisomer thereof.

24. The compound of formula (I) described in claim 1, or a pharmaceutically acceptable salt or stereoisomer thereof.

25. The following formula (X) 【Chemistry 12】 Or the following formula (XI) 【Chemistry 13】 (In the formula, G, R 2 , R 3 , R 4 , R 5 , and R 6 is as described in claim 1, PG is a protecting group selected from the group consisting of tert-butoxycarbonyl (BOC), benzyloxycarbonyl (Cbz), fluorenylmethyleneoxycarbonyl (Fmoc), and allyloxycarbonyl (Alloc). A compound of [unclear].

26. The following formula (A) 【Chemistry 14】 Or the following formula (A') 【Chemistry 15】 (wherein G, R1, R2, R3, R4, R5, R6 and R7 are as described in claim 1, R 12 C 1-4 -alkyl, aryl, -CH 2 -Ayl, NH-SO 2 -C 1-3 -It is alkyl.) It is a compound of A compound that is an ester of any of the compounds described in claim 1.

27. R 12 A compound of formula (A) or formula (A') according to claim 26, wherein is methyl.

28. A pharmaceutical composition comprising a compound described in any one of claims 1, 2, 16 to 24, 26, and 27, or a pharmaceutically acceptable salt or stereoisomer thereof, and optionally comprising one or more pharmaceutically acceptable carriers and / or excipients.

29. The pharmaceutical composition according to claim 28, for use in the treatment of inflammatory diseases or autoimmune diseases.

30. The pharmaceutical composition according to claim 28, for use in the treatment of a disease selected from the group consisting of systemic lupus erythematosus (SLE), interferonopathy, Eicardi-Gutierre syndrome, age-related macular degeneration (AMD), amyotrophic lateral sclerosis (ALS), inflammatory bowel disease (IBD), chronic obstructive pulmonary disease (COPD), Bloom syndrome, Sjögren's syndrome, Parkinson's disease, heart failure and cancer, systemic sclerosis (SSc), non-alcoholic steatohepatitis (NASH), and interstitial lung disease (ILD).

31. The pharmaceutical composition according to claim 28, for use in the treatment of a disease selected from the group consisting of systemic lupus erythematosus (SLE), interferonopathy, Eicardi-Gutierre syndrome, age-related macular degeneration (AMD), amyotrophic lateral sclerosis (ALS), inflammatory bowel disease (IBD), chronic obstructive pulmonary disease (COPD), Bloom syndrome, Sjögren's syndrome, and Parkinson's disease.

32. The pharmaceutical composition according to claim 28, for use in the treatment of a disease selected from the group consisting of systemic sclerosis (SSc), non-alcoholic steatohepatitis (NASH), interferonopathy, and interstitial lung disease (ILD).

33. The pharmaceutical composition according to claim 32, wherein the interstitial lung disease (ILD) is progressive fibrous interstitial lung disease (PF-ILD).

34. The pharmaceutical composition according to claim 33, wherein the progressive fibrous interstitial lung disease (PF-ILD) is idiopathic pulmonary fibrosis (IPF).

35. The pharmaceutical composition according to claim 28, for use in the treatment of a disease selected from the group consisting of age-related macular degeneration (AMD), heart failure, COVID-19 / SARS-CoV-2 infection, nephritis, renal fibrosis, metabolic disorders, vascular diseases, cardiovascular diseases, and cancer.

36. A pharmaceutical composition comprising one or more active agents selected from the group consisting of anti-inflammatory agents, anti-fibrotic agents, anti-allergic agents / antihistamines, bronchodilators, β2 agonists / beta-mimetics, adrenergic agents, anticholinergic agents, methotrexate, mycophenolate mofetil, leukotriene modifiers, JAK inhibitors, anti-interleukin antibodies, nonspecific immunotherapy agents, cytokine / chemokine receptor modifiers, Toll-like receptor agonists, immune checkpoint modulators, anti-TNF antibodies, and anti-BAFF antibodies, in combination with any one of the compounds described in claims 1, 2, 16-24, 26, and 27, or pharmaceutically acceptable salts or stereoisomers.

37. The pharmaceutical composition according to claim 36, wherein a compound or pharmaceutically acceptable salt or stereoisomer according to any one of claims 1, 2, 16-24, 26, and 27 is combined with one or more antifibrotic agents selected from the group consisting of pirfenidone and nintedanib.

38. The pharmaceutical composition according to claim 36, wherein a compound or pharmaceutically acceptable salt or stereoisomer according to any one of claims 1, 2, 16-24, 26, and 27 is combined with one or more anti-inflammatory agents selected from the group consisting of NSAIDs and corticosteroids.

39. The pharmaceutical composition according to claim 36, wherein a compound or pharmaceutically acceptable salt or stereoisomer according to any one of claims 1, 2, 16 to 24, 26 and 27 is combined with one or more active agents selected from the group consisting of bronchodilators, β2 agonists / beta-mimetics, adrenergic agonists, anticholinergics, interferons and other cytokines / chemokines.

40. The pharmaceutical composition according to claim 36, wherein the compound or pharmaceutically acceptable salt or stereoisomer described in any one of claims 1, 2, 16 to 24, 26 and 27 is combined with one or more anti-interleukin antibodies selected from the group consisting of anti-IL-23 antibody, anti-IL-17 antibody, anti-IL-1 antibody, anti-IL-4 antibody, anti-IL-13 antibody, anti-IL-5 antibody, anti-IL-6 antibody, anti-IL-12 antibody and anti-IL-15 antibody.

41. The pharmaceutical composition according to claim 36, wherein the compound or pharmaceutically acceptable salt or stereoisomer described in any one of claims 1, 2, 16-24, 26, and 27 is combined with one or more active agents selected from the group consisting of risankizumab (an anti-IL-23 antibody), tocilizumab (an anti-IL-6 antibody), adalimumab (an anti-TNF antibody), belimumab (an anti-BAFF antibody), and etanercept (an anti-BAFF antibody).

Images